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Sleep-related problems are rapidly growing public-health concerns that often result in 
adverse short-term consequences (e.g., reduced quality of life) and long-term health effects 
(e.g., cardiovascular disease). However, the relation between sleep problems and chronic 
kidney disease (CKD) has been under-investigated. To better understand this relation, we 
addressed three aims.  
The first aim was to examine temporal trends in the prevalence of 5 self-reported sleep 
problems in U.S. adults and their associations with CKD and all-cause mortality, using data from 
5 National Health and Nutrition Examination Surveys (2005-14). The prevalence of trouble 
sleeping and diagnosed sleep disorder increased over the decade, while nocturia (urinating ≥2 
times/night), inadequate sleep (<7 hours/night), and excessive sleep (>9 hours/night) remained 
stable. All sleep problems, except inadequate sleep, were more common among adults with 
CKD than without CKD, especially for excessive sleep and nocturia, which were positively 
associated with all-cause mortality.  
Second, we conducted a large retrospective cross-sectional study of obstructive sleep 
apnea (OSA) in U.S. veterans who sought care in Veteran Administration (VA) facilities in fiscal 
year (FY) 2018 to better understand the population burden of OSA and its relation with CKD and 
its risk factors. Using data from 6.2 million veterans for FY2014-18, we estimated OSA point 
prevalence at the last visit to a VHA facility in FY2018 (index time T) and period prevalence of 
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OSA (excluding prevalent cases at T) going back to the start of FY2014. Period 
prevalence for each duration was estimated by taking into account left censoring of veterans 
followed back for different durations. At time T, OSA point prevalence was 24.9% in veterans 
with CKD and 15.2% in those without CKD. The overall 60-month period prevalence was 11.6% 
and was positively associated with CKD, obesity, being male, having hypertension, or diabetes, 
and inversely associated with age ≥65.  
Lastly, we conducted a large retrospective cohort study of U.S. veterans to test the 
hypothesis that CKD is a mediator in the causal pathway linking race/ethnicity with OSA 
incidence. Four statistical methods of mediation analysis with different advantages and 
limitations were used: informal difference method, 4-way decomposition, flexible mediation 
analysis, and dynamic path analysis. Blacks and Hispanics had higher incidence rates than did 
non-Hispanic Whites. The percentages of the total race/ethnicity effects mediated by CKD were 
small and similar using all 4 mediation methods; e.g., using flexible mediation analysis, the 
percentage of the Black/White effect on OSA incidence mediated by CKD was 5.8%. However, 
when CKD and its 3 risk factors were treated jointly as mediators in flexible mediation analysis, 
the percentage mediated increased to 30.3%.  
The high prevalence of sleep problems including OSA among persons with CKD, their 
associations with mortality, and the mediated effect by CKD on racial disparity in OSA incidence 
suggest their potential importance to clinical practice. Future work could address the feasibility 
of early identification, objective characterization and management of sleep problems among 
patients with CKD, and studying the effects of proactive practices including control of mediators 






Sleep-related problems such as getting too little sleep or trouble sleeping are rapidly 
growing public-health concerns because they often result in adverse short-term consequences 
such as stress responsivity and reduced quality of life as well as long-term health consequences 
such as hypertension and cardiovascular disease.1 Its increasing prevalence may be due to 
round-the-clock, night-owl lifestyles, elevated stress, and increasing awareness of the problem, 
leading to more reporting, increasing physiological conditions (e.g., obesity and diabetes) and 
the increasing use of mediations that may interfere with sleep, and societal factors such as 
natural disasters and pandemics.2 Sleep problems (whether sleeping too much or not enough ) 
are associated with mortality and mental disorders especially depression.3 A common but often 
unrecognized sleep disorder, sleep apnea, is a public health concern causing repetitive 
cessation of breathing while a person is sleeping. Obstructive sleep apnea (OSA), characterized 
by transient airway occlusion, is the most common form of sleep-disordered breathing.4  Fifty 
percent of women and 37% of men were reported to have OSA in two recent studies.5,6 In 
contrast, central sleep apnea (CSA) usually involves brain dysfunction rather than significant 
upper airway obstruction.7 Not only does OSA appear to increase the risk of physical and 
psychological diseases, but it also impairs the quality of life as well as cognitive function,8,9 
including vigilance, attention, executive functioning, memory, and motor coordination.10  
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Chronic Kidney Disease (CKD), a common disorder worldwide with the prevalence 
ranging from 3% to 18% worldwide11 and nearly 15% in the US adult population,12 is defined by 
abnormal kidney function (indicated by an estimated glomerular filtration rate (eGFR) < 60 
mL/min/1.73 m2) or structural damage (indicated by urine albumin-to-creatinine ratio (UACR) > 
30 mg/g) persisting for at least three months. About 6% of CKD patients end up with end-stage 
renal disease (ESRD).13,14 CKD itself is an important risk factor for all-cause mortality, especially 
cardiovascular mortality.12,15,16  
Recent studies have found that OSA is associated with higher risk of cardiovascular 
disease, especially stroke.17,18,19 However, unlike the well-established association between OSA 
and cardiovascular morbidity and mortality, the relation between OSA and CKD is not fully 
understood. A vicious cycle--positive feedback loop--may exist, in which OSA increases the risk 
of CKD, which in turn increases the risk or severity of OSA.20 
Patients with and without CKD could have different etiologies and clinical 
manifestations of OSA: comparing to people without CKD, OSA patients with advanced CKD 
tend to be less obese, report less frequent snoring, and more frequently experience apnea 
during sleep, unrefreshing sleep, and morning headache.21,22 Therefore, the associations 
between certain CKD risk factors (older age, male sex, obesity) and the risk of OSA are weak in 
patients with ESRD in spite of these major determinants of OSA in the general population.23,24,25 
Veterans are more vulnerable to sleep disturbance because of the high prevalence of 
possible risk factors including obesity, male sex, hypertension, depression, posttraumatic stress 
disorder, substance use, and other comorbidities comparing to the general population.26,27,28,29 
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However, there is a dearth of research accurately estimating prevalence of sleep apnea among 
the veteran population. Different methods were used to estimate prevalence of sleep apnea, so 
prevalence estimates of sleep apnea might not be comparable.30,31 Few studies have addressed 
the importance of sleep apnea prevalence in veterans with CKD versus veterans without CKD, 
and they involve relatively small sample sizes or selected study populations.32 
Relative to non-Hispanic Whites (hereafter “Whites”), non-Hispanic Blacks (hereafter 
“Blacks”) have a higher prevalence of CKD, a higher risk of progressing to ESRD, an earlier start 
of dialysis, and a higher mortality rate after ages 56. The racial inequality in CKD may result 
from the excess prevalence of important causal risk factors for CKD such as diabetes, 
hypertension, dietary factors and lifestyle in Blacks. The elevated prevalence of OSA in Blacks 
relative to Whites is convincing evidence of racial inequalities in the development or course of 
OSA.33 Moreover, Hispanics and racial minorities showed higher prevalences of OSA compared 
to Whites.34,35 However, research examining CKD as a possible mediator of racial difference in 
OSA is limited. Previous studies have examined sleep-related variables as mediators of the race 
effect on cardiometabolic diseases36 and blood pressure.37 
This dissertation has three aims related to sleep problems, CKD, and OSA in adults. The 
first aim, using data from National Health and Nutrition Examination Surveys, is to describe the 
prevalence and temporal trends in the U.S. of five self-reported sleep problems—trouble 
sleeping, diagnosed sleep disorder, nocturia, inadequate sleep, excessive sleep—and their 
associations with CKD prevalence and CKD-specific mortality. The second aim, using data from 
U.S. Veterans Administration (VA) facilities, is to estimate the point prevalence and period 
prevalence of OSA among veterans with and without CKD and to evaluate their associations 
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with several possible risk factors for OSA. The third aim, again using VA data, is to assess 
whether and to what extent the excess incidence of OSA in racial/ethnic groups relative to 
Whites could be explained by CKD serving as a mediator in the causal pathways linking 
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Aim 1: US Trends in Prevalence of Sleep Problems and Associations With Chronic Kidney 
Disease and Mortality 
Abstract   
 
Background: To better understand the relation between sleep problems and chronic kidney 
disease (CKD), we examined temporal trends in the prevalence of self-reported sleep problems 
in US adults and their associations with CKD and all-cause mortality. 
Methods: Using data from 27,365 adult participants in 5 biannual National Health and 
Examination Surveys (2005-6 through 2013-14), we studied 5 self-reported sleep problems: 
trouble sleeping, sleep disorder, nocturia (urinating ≥2 times/night), inadequate sleep (<7 
hours/night), and excessive sleep (>9 hours/night); plus a composite index. We conducted 3 
types of analysis: temporal trends in the prevalence of each sleep measure by CKD status, using 
model-based standardization; cross-sectional analysis of associations between 4 CKD measures 
and each sleep measure, using logistic regression; and survival analysis of the association 
between each sleep measure and mortality, using Cox regression.  
Results: The prevalence of trouble sleeping and sleep disorder increased over the 5 surveys by 
3.6% and 2.8%, respectively, while the other sleep problems remained relatively stable. All 
sleep problems, except inadequate sleep, were more common during the study period among 
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adults with CKD than without CKD (40.3% vs. 21.4% for nocturia; 5.0% vs 1.9 % for excessive 
sleep; 30.0% vs. 25.2% for trouble sleeping; and 11.6% vs. 7.9% for sleep disorder). Both eGFR 
<30 mL/min/1.73m2 and albuminuria were positively associated with nocturia and excessive 
sleep. Excessive sleep and nocturia were also associated with higher mortality (adjusted hazard 
ratio for>9 vs. 7-9 hours/night = 1.7; 95% CI: 1.3, 2.1; and for nocturia=1.2; 95% CI: 1.1, 1.4).  
Conclusion: The high prevalence of sleep problems among persons with CKD and their 
associations with mortality suggest their potential importance to clinical practice. Future work 






Sleep abnormalities are associated with several health conditions including chronic 
kidney disease (CKD) and end-stage renal disease (ESRD)1. The prevalence of sleep problems—
including difficulty falling asleep, nightmares, restless legs syndrome, and sleep apnea—has 
been reported to range from 6% to 49% in older patients in the general population2 and as high 
as 80% in patients with ESRD.1,2 In addition, poor sleep quality has been reported in40-85% of 
dialysis patients and up to 85% of patients with CKD.3,4 Higher prevalences of inadequate sleep, 
frequent use of sleeping pills, restless legs syndrome, and nocturia were observed in individuals 
with CKD stages 1-2 than in individuals without CKD (i.e., persons with vs. without an albumin-
to-creatinine ratio [ACR] ≥ mg/g among those with an estimated glomerular filtration rate 
[eGFR] ≥ 60 mL/min/1.73 m2).5   
The higher burden of sleep problems in patients with kidney disease is important, as 
they been linked with all-cause mortality.6 Sleep problems may be an important risk factor for 
mortality in the ESRD patient population.7 While the prevalence of sleep disturbances has been 
shown to be increasing among US adults,6 temporal trends in sleep problems have been sub-
optimally examined in US adults with kidney disease. Moreover, few studies with large national 
samples have been conducted to document the frequency of sleep problems by CKD status in 
the United States (US) or to examine their associations with morbidity and mortality.8   
Our study aims were first to describe the prevalence and temporal trends in the US of 
five self-reported sleep problems—trouble sleeping, sleep disorder, nocturia, inadequate sleep, 
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excessive sleep; plus a composite measure—and second, to examine the associations of those 
sleep problems with CKD prevalence and mortality by CKD status.   
Methods 
Data source and study design 
We utilized data on US adults (aged ≥20 years) with and without CKD from 5 biennial 
National Health and Nutrition Examination Surveys (NHANES), conducted by the National 
Center for Health Statistics of the Centers for Disease Control and Prevention between 2005-06 
and 2013-14. A series of cross-sectional and longitudinal (trend) analyses were conducted to 
examine the prevalence of sleep problems and their associations with CKD. NHANES is designed 
to assess the health and nutritional status of US adults and children.9 The surveys include 
demographic, socioeconomic, dietary, and health-related questions from a representative 
sample of noninstitutionalized US residents, with oversampling of people 60 and older, African 
Americans, and Hispanics. The analysis was limited to 27,365 NHANES participants during the 
10-year study period (2005-14) who were 20 years and older and not on renal replacement 
therapy at the time of examination. All NHANES participants were required to give written 
informed consent as part of the NHANES study procedures. This study was deemed “non-
regulated” by the Institutional Review Board at the University of Michigan, as NHANES provides 
publicly available de-identified data as part of the Centers for Disease Control and Prevention’s 




We examined four self-reported sleep variables: 1) trouble sleeping, obtained from 
responses to the question, “Have you ever told a doctor or other health professional that you 
have trouble sleeping?" 2) sleep disorder, obtained from responses to the question, “Have you 
ever been told by a doctor or other health professional that you have a sleep disorder?" 3) 
nocturia, obtained from responses to the question, “During the past 30 days, how many times 
per night did you most typically get up to urinate, from the time you went to bed at night until 
the time you got up in the morning?” and 4) total hours of sleep per night, obtained from 
responses to the question, “How much sleep do you usually get at night on weekdays or 
workdays?” Responses to the nocturia question were dichotomized as two or more times per 
night (nocturia) or less frequently; and responses to the sleep-duration question were 
categorized according to national and international guidelines10 as less than 7 hours per night 
(inadequate sleep), 7 to 9 hours (recommended sleep), and more than 9 hours (excessive 
sleep). In addition, a composite sleep-problem index was created by first summing indicators of 
all 5 sleep problems. Because excessive sleep was nearly unrelated to the other sleep problems 
(and mutually exclusive with inadequate sleep), it was excluded from the index, resulting in a 
reliable composite measure that is internally consistent (Cronbach's alpha = 0.57). 
Demographic information (age, sex, and race/ethnicity) was collected during the 
interview of each participant. Race/ethnicity was categorized into four groups: Hispanic; non-
Hispanic White; non-Hispanic Black/African American; and non-Hispanic other race. 
Hypertension and diabetes were defined by any of three criteria: self-report of each condition 
as told by a health professional; self-reported use of condition-specific medications; and 
laboratory measurements (systolic and diastolic blood pressure, hemoglobin level [A1c], and 
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blood sugar). Obesity was defined as a body mass index (BMI) ≥30 kg/m2. Serum creatinine 
levels were corrected for different laboratory methods used in different years.11 Urine albumin 
was measured by a solid-phase fluorescein immunoassay and urine creatinine by the enzymatic 
method.12 Smoking status was defined as currently smoking on all or some days. Histories of 
cancer, cardiovascular disease, and chronic respiratory disease were based on self-reports as 
told by a health professional. Prescription medications were recorded by the interviewer from 
the bottles provided by the participant, and medications that affect drowsiness and cognition 
were extracted from these data and created indicators for sedatives, stimulants, and other 
drugs (Table A1). 
Because CKD is diagnosed on the basis of both reduced kidney function indicated by low 
eGFR and kidney damage indicated by a high urinary ACR or albuminuria, we used four 
measures of CKD in our analyses:13  
1. CKD status (binary; CKD vs. no CKD): eGFR < 60 mL/min/1.73m2 (using the CKD-EPI 
equation14) and/or ACR ≥ 30 mg/g versus eGFR ≥ 60 mL/min/1.73m2 and ACR < 30 
mg/g (reference group).   
2. eGFR category (ordinal): eGFR ≥ 60 mL/min/1.73 m2 (reference group); 30 ≤ eGFR < 
60 mL/min/1.732 ; and eGFR < 30 mL/min/1.73 m2.  
3. ACR category (ordinal): normal to mildly increased (ACR < 30 mg/g; reference 
group); moderately increased (30 mg/g ≤ ACR ≤ 300 mg/g); and severely increased 
(ACR > 300 mg/g).   
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4. CKD prognosis category defined in KDOQI13 (ordinal, based on the combination of 
eGFR category and ACR category): low risk (no CKD; same reference group as in #1), 
moderate increased risk, high risk, and very high risk (see Table A4 for details). 
All-cause mortality data were available for 27,322 (99.8%) of the 27,365 participants. All 
5 survey cohorts were followed from their baseline interviews (2005-2014) to the end of 2015. 
Thus, the follow-up duration of study participants could range from as little as 1 year to as 
much as 11 years; the median observed follow-up was 77 months. Vital status and date of 
death were ascertained from the National Death Index (NDI). The primary determination of 
mortality status for participants was based on matching survey records to the NDI. If a source of 
mortality other than NDI was available, the participant was considered deceased. The publicly 
available records from the NDI were linked with NHANES by the National Center for Health 
Statistics. The linkage of NHANES surveys to the NDI involved identifying eligible participants 
from the NHANES surveys, creating base submission records plus any alternative records, 
merging base submission records with NDI data, executing the match process, reviewing match 
results, selecting matches and determining vital status.15 
 
Statistical analysis 
 Temporal trends in the prevalence of each sleep problem and the mean composite 
index were estimated across the 5 NHANES surveys, by CKD status (CKD vs. no CKD). The crude 
and standardized prevalence of the 5 sleep problems were estimated for each two-year survey 
(2005-06 to 2013-14). Weighted linear regression, as recommended by the Centers for Disease 
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Control and Prevention,16 was used to directly standardize for age, sex, and race/ethnicity, 
using the 2000 US population as the standard17 and treating survey year as a nominal variable. 
The ACR was standardized to the covariate distribution of the 2005-06 cohort. To test for a 
monotonic trend, we treated survey year as an interval variable (coded 1-5).  
 Cross-sectional associations of each CKD measure (predictor) with each sleep problem 
(outcome) were examined using data from all 5 NHANES surveys (2005-14). Weighted logistic 
regression was used to estimate the adjusted prevalence odds ratios (OR) and 95% confidence 
intervals (CI). In this analysis, amount of sleep each night was treated as a 3-category outcome, 
using multinomial logistic regression to estimate the effects of each CKD predictor on 
inadequate and excessive sleep vs. normal sleep. These associations were adjusted for survey 
year, age, sex, race/ethnicity, diabetes, hypertension, obesity, and use of one or more 
medications thought to affect sleep problems. To examine age as a possible modifier of the 
associations between CKD measures and sleep variables, we stratified by age to compare adults 
who were 65 and older with those who were under 65.  
The association between each sleep problem as well as the composite index observed at 
baseline interviews in all 5 surveys (2005 to 2014) and all-cause mortality through 2015 was 
estimated in separate models using Cox regression. The hazard ratio (HR and 95% confidence 
interval [CI]) for the effect of each sleep problem and composite index on time to death was 
adjusted for survey year, age, sex, race/ethnicity, CKD status, hypertension, diabetes, obesity, 
current smoking status, cancer, CVD, chronic respiratory disease, the selected medications, and 
the other sleep problems (excluding the composite index). To assess CKD status as a potential 
modifier of the effect of each sleep problem on mortality, product terms for each sleep variable 
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and CKD status were added to the models. In addition, separate analyses were conducted for 
participants with and without CKD. 
Multiple imputation was implemented to impute missing values of trouble sleeping 
(0.05% missing), sleep disorders (0.2% missing), nocturia (29.0% missing), sleep amount (0.2% 
missing), eGFR (6.5% missing), and ACR (2.5% missing), assuming data were missing at 
random.18 First, we imputed values for the missing data 25 times by sampling from the chained 
equations using PROC MI procedures within SAS software, which included auxiliary variables 
that may contain information about the missing data, variables and outcomes involved in the 
planned analysis, and variables accounting for the clusters and strata.19 From the complete 
variables and the imputed set, 25 complete datasets were created. Second, we analyzed the 25 
complete data sets using SURVEY procedures within SAS. Finally, we combined the 25 
parameter estimates and standard errors to calculate pooled estimates and standard errors 
using PROC MIANALYZE procedures within SAS, which reflect the variability of the imputation 
process along with the complex sampling design.20 
Because many participants in our survival analysis were followed for several years (from 
as early as January 1, 2005 to as late as December 31, 2015), the status of their sleep problems 
could have changed during follow-up, possibly leading to bias in effect estimation. 
Unfortunately, we did not have data on changing sleep problems after baseline interviews, so 
we could not treat each sleep problem as time-dependent. Therefore, we conducted a 
sensitivity analysis by restricting the follow-up of each survey participant to no more than 1 
year. Although changes in sleep problems could still occur over 1 year, the potential for bias 
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would be reduced appreciably, and the number of deaths in 1 year yielded sufficient estimation 
precision.  
All analyses were performed in SAS version 9.4 and account for the survey data 




Table 1 shows summary statistics for selected baseline variables in 27,365 participants. 
The mean age was 47 years; 48% were male and 68% were non-Hispanic Whites. Compared to 
participants without CKD, those with CKD were more likely to be older, female, have larger 
BMIs, have diabetes, hypertension, cancer, CVD, and worsening memory. 
Time trends in the age-sex-race-standardized prevalence of each sleep problem and the 
composite sleep-problem index during the study period are displayed in Figure 1.a-f and Table 
A2. Overall, there was a steady rise of 3.6% between 2005-06 (24.1%) and 2013-14 (27.7%) in 
the prevalence of reported trouble sleeping (P for trend < 0.001; Figure 1.a) and a sharper rise 
of 3.1% between 2009-10 (7.1%) and 2013-14 (10.2%) in the prevalence of reported sleep 
disorders (P for trend < 0.001; Figure 1.b). In contrast, there was an overall decrease of 2.9% in 
the prevalence of inadequate sleep between 2007-08 (38.3%) and 2013-14 (35.4%) (P for trend 
= 0.53; Figure 1.c). The other sleep problems remained fairly stable or varied inconsistently 
during the study period (Figures 1.d-e). The prevalences of all 5 sleep problems and the 
composite index were greater for persons with CKD than without CKD during most survey years 
(Table A2). There was a steady increase of 2.7% between 2005-06 (23.0%) and 2013-14 (25.7%) 
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in the prevalence of the composite index score >1 (P for trend = 0.036; Figure 1.f). There was a 
downward spike in 2011-12 in the prevalences of trouble sleeping, inadequate sleep, and the 
composite index among CKD patients, deviating from those overall trends. Since the sleep 
questions did not change for that one survey among any group, we cannot explain the unusual 
deviation.   
Table 2 shows the cross-sectional associations between each of 4 CKD measures treated 
as predictors--CKD status, ACR category, eGFR category, and CKD prognostic category (based on 
both ACR and eGFR; refer to Table A4 for the joint distribution of these two CKD measures)—
and each sleep problem treated as the outcome. CKD status was most strongly associated with 
excessive sleep (OR = 2.2; 1.8-2.5) and nocturia (OR = 1.3; 1.1-1.4); it was inversely associated 
with trouble sleeping (OR = 0.88; 0.78-0.99) but not associated with inadequate sleep or sleep 
disorder. ACR category was more strongly and positively associated with each sleep problem 
than was eGFR category, except for excessive sleep. Compared with eGFR ≥60 mL/min/1.73m2, 
the adjusted OR for excessive sleep was 2.4 (1.9, 3.1) for eGFR = 30-59 and 5.8 (3.4, 9.8) for 
eGFR <30. Compared with ACR <30 mg/g, the adjusted OR for nocturia was 1.2 (1.1, 1.4) for 
ACR = 30-300 mg/g and 1.6 (1.3, 2.0) for ACR >300 mg/g. Positive monotonic associations were 
observed between CKD prognosis category and nocturia and between CKD prognosis category 
and excessive sleep (P for trend < 0.001). Nocturia and excessive sleep were positively 
associated with CKD prevalence (P < 0.001) and monotonically associated with the three 
polytomous measures of CKD (P for trend < 0.001).  Weighted and standardized prevalences of 




The weighted prevalence of each sleep problem and the index score are shown in Table 
3. The overall prevalences, in order from most to least common, were: inadequate sleep 
(36.5%), trouble sleeping (25.9%), nocturia (24.3%), sleep disorder (8.5%), and excessive sleep 
(2.4%). For all problems except inadequate sleep, the prevalence was greater in persons with 
CKD than without CKD. More than 60% of the study population had a sleep-problem index 
score greater than zero. 
Crude and mutually adjusted HRs for the estimated effects of the 5 sleep problems on 
all-cause mortality, are shown in Table 4. Overall, the sleep problem with the strongest 
association with mortality was excessive sleep (>9 hours/night), which was reported less 
frequently (2.4%) than the other sleep problems (Table 3). Compared with recommended sleep 
(7-9 hours/night), the adjusted HR for excessive sleep was 1.7 (1.3, 2.1) in the total study 
population. The crude association (HR = 3.6) was reduced appreciably with covariate 
adjustment; and it was stronger for persons without CKD (P for interaction = 0.08) but did not 
vary much by age (P for interaction = 0.28; data not shown). A weaker overall association was 
found for nocturia (adjusted HR = 1.2; 1.1, 1.4) with little difference between age groups; and 
little or no association overall or by age was observed for trouble sleeping, sleep disorder, and 
inadequate sleep.    
The associations of the sleep-problem index and excessive sleep with mortality, 
mutually adjusted for each other, are shown in Table 5. A positive monotonic association in the 
total population was observed for the index score (P for trend = 0.01), and a moderate 
association was observed for excessive sleep (adjusted HR = 1.7; 1.3, 2.1). While the association 
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with the index score was a slightly stronger in persons with CKD, the association with excessive 
sleep was stronger in persons without CKD.   
Results of the sensitivity analysis in which follow-up for mortality was limited to one 
year are shown in Table 6. The HR estimates are similar to the estimates in the main analysis 
with full follow-up to the end of 2015 (Table 4), but with wider confidence intervals. These 
results suggest little bias resulting from unmeasured changes in the prevalence of sleep 
problems during follow-up in the main analysis. 
 
Discussion  
Our analysis of data from a series of contemporary, nationally representative surveys 
over the past decade shows that the prevalence of self-reported sleep problems—trouble 
sleeping, sleep disorders, nocturia, inadequate sleep, and excessive sleep—were generally 
higher in adults with CKD than those without CKD in the US. We observed monotonic 
associations between severity of CKD (based on ACR, eGFR, and CKD prognostic categories) and 
sleep problems adjusting for potential confounders. The sleep problems most strongly and 
consistently associated with all CKD measures were excessive sleep and, to a lesser extent, 
nocturia. All measured sleep problems, except trouble sleeping among CKD patients, were 
positively associated with mortality, and we found a dose-response association between the 
number of sleep problems and mortality. The sleep problem with the strongest association with 
mortality was the one with the lowest prevalence, excessive sleep, which likely reflects the 
influence of major chronic health problems. These findings highlight the importance of 
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remaining alert to the presence of sleep problems among those with CKD both by primary care 
and by specialist providers. 
The prevalence of reported sleep disorders, especially trouble sleeping and sleep 
disorder, has risen over the past 10 years and almost doubled among persons with CKD. These 
findings are supported by evidence in the general population of the increasing prevalence of 
sleep-disordered breathing including obstructive sleep apnea (OSA), purportedly due in part to 
the obesity epidemic and an aging society.2,21 Thus, the increasing prevalence of self-reported 
sleep disorders in this study may not only reflect an artifactual increase in reporting.   
The increasing prevalence of self-reported insomnia and excessive daytime sleepiness 
among the US population from 2002 to 2012 was reported by Ford et al.22 Moreover, sleep 
duration has been declining over the years in the US and reached an average of 7.2 hours per 
night in 2012.23 According to Knutson et al.,24 who compiled time-diary data from 8 national 
studies conducted between 1975 and 2006, the percentage of US adults having less than 6 
hours sleep per night (“short sleepers”) fluctuated inconsistently from a low of 7.5% in 1992-94 
to a high of 11.8% in 1998-99; the prevalence in 2006 was 9.3%. In contrast, we found the 
prevalence of <6 hours sleep per night in 2005-06 to be 13.4% and relatively stable through 
2013-14 (data not shown for <6 hours/night). This inconsistency may be due to the different 
methods used to measure sleep duration, i.e., time-diaries used by Knutson et al.24 versus 
recall-based self-reports used in our study. 
We found that the low eGFR category was associated, as expected, with higher 
prevalences of nocturia and excessive sleep, but not with the other sleep problems; in fact, the 
22 
 
high eGFR category was associated with inadequate sleep, which may, at least in part, 
potentially reflect longer work hours23 or other factors (e.g., stress, anxiety or depression). We 
were not, however, able to assess the influence of employment status or work hours on the 
associations with eGFR. 
Plantinga et al.5 found a higher prevalence of sleep disorders and inadequate sleep (≤6 
hours/night) for persons with CKD stages 1 and 2, but not for stages 3 and 4, relative to persons 
without CKD. We found a similar but very weak association with inadequate sleep (<7 
hours/night) but little or no association with sleep disorder (Table 2). Similar to Plantinga et al.,5 
we found that nocturia was strongly associated with CKD, regardless of the method used to 
characterize CKD. It is possible that people with lower eGFR tend to be more often on multiple 
medications, be more fatigued, and therefore have longer sleep duration (which may clinically 
be (mis)interpreted as ‘good sleep’). Since GFR has a weaker association with obesity than do 
the other CKD measures,25 another possible explanation is that patients with lower eGFR may 
not be getting the requisite sleep diagnostic work-up as frequently, due either to low index of 
suspicion by the clinician, or greater attention to kidney-specific complications in the setting of 
having to deal with multiple clinical domains (e.g., blood pressure control, management of 
anemia, bone and mineral metabolism and fluid-electrolyte abnormalities, CKD progression, 
etc.), in the limited time typically available for an average clinical encounter. This could result in 
the patient not receiving a sleep study, and thus not being aware of the presence of a sleep 
disorder.   
Although only 2.4% of participants reported excessive sleep, that problem was most 
strongly associated with all four CKD measures (Table 2) and all-cause mortality in the total 
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sample (Table 4). For the associations between sleep duration and all-cause mortality, a 
positive monotonic association was found in participants without CKD, indicating that more 
sleep is associated with mortality; but a U- or J-shaped association was observed among those 
with CKD, indicating that both inadequate and excessive sleep are associated with mortality 
(Table 4). A similar U-shaped association has been reported in previous studies.6,26,27,28  Sleep 
fragmentation, immune dysfunction, photoperiodic abnormalities, depression, underlying 
disease process such as sleep apnea, heart disease, or failing health are potential mechanisms 
linking excessive sleep duration with mortality.29 The prevalence of sleeping more than 9 hours 
a night in the US varied a little across studies: 5% reported excessive sleep in 2006 in Patel et 
al.,30 3.6% in 2014 according to Liu et al.,31 and 2.4% in our study.  
Unlike the association between inadequate sleep and mortality, the underlying 
mechanisms for the association between excessive sleep and mortality are yet to be fully 
investigated. This association could be confounded by other unmeasured risk factors for 
mortality such as comorbidities.32 Comorbidities such as chronic respiratory disease, cancer, 
and CVD were adjusted for in the study, but they were self-reported; thus, their 
misclassification may have limited control for confounding. Furthermore, excessive sleep could 
simply be a marker of poor sleep quality, chronic pain, increased duration of rapid eye 
movement sleep, or soporific side effects of medications.33 
Short sleep duration has also been found in several systematic reviews to be associated 
with a number of adverse health outcomes including mortality.6,27,28,34,35,36 Possible mechanisms 
for the health effects of inadequate sleep are endocrinologic, immunologic, and metabolic 
factors such as increased ghrelin and decreased leptin,37,38 chronic inflammation, altered 
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cortisol secretion and growth hormone metabolism,39,40 the development of hypertension from 
increased sympathetic nervous system activity, and changes in circadian rhythm.41 In our study, 
however, we found little positive association between inadequate sleep and CKD or mortality. 
That apparent discrepancy might be due to our data being derived from self-reports, rather 
than more objective methods such as actigraphy or polysomnography, which may not strongly 
correlate with self-reports from surveys.32   
We found that nocturia was strongly associated with CKD and mortality regardless of 
the method used to characterize CKD. Nocturia is one of the most common symptoms in 
patients with CKD,42 with a prevalence of 40% in our study. A trend of increased mortality with 
increased number of voiding episodes in the general population was also reported in NHANES lll 
participants.43 Krol et al. reported that nocturia was associated with albuminuria,44 which is 
consistent with our finding of a dose-response association with ACR (Table 2).  Studies have 
showed that osmotic diuresis rather than water diuresis or urea excretion is the main 
mechanism of nocturia in CKD.45 Possible mechanisms of nocturia include an overall increase in 
urine production (secondary to diminished ability to concentrate urine by a poorly functioning 
kidney), resulting in continued higher volume of, urine production even at night, a reduced 
bladder capacity, or any sleep disorder.46 Aside from urologic conditions, nocturia may also 
reflect multiple underlying renal or systemic diseases.47 In addition, it is linked to urinary 
urgency, prostate cancer, OSA, depression, and the metabolic syndrome.48,49 
An important limitation of this study concerns the measurement of sleep problems. 
First, self-reports may be inaccurate, possibly resulting in bias in estimating the prevalence of 
the sleep problems or their associations with CKD or mortality. Second, detailed information 
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was lacking on reported sleep problems, especially relevant for trouble sleeping and sleep 
disorder. For trouble sleeping, we did not know the frequency, duration, or timing of reported 
problems. For sleep disorder, we did not know the type or nature of the disorder that a doctor 
presumably told the patient he or she had. Third, persons with CKD, especially advanced CKD, 
are generally more likely than those without CKD to be seeing a physician on a regular basis. 
Therefore, they may have been more likely to report communicating with their doctors about 
sleep problems and specific sleep disorders, even if those two problems were not more 
frequent or severe. Finally, although our composite sleep index was an ad hoc measure, there is 
evidence of its construct validity in Table 5, where it was monotonically associated with 
mortality, consistent with our hypothesis; and we found the index to have good reliability with 
Cronbach’s alpha of 0.57.  
Another limitation is the cross-sectional design for estimating associations between CKD 
and sleep problems. Thus, we cannot determine whether associations may have been due to 
the effects of CKD on sleep problems, as hypothesized, or to the possible effects of sleep 
problems on CKD.50 Finally, a limitation of this study is residual confounding due to unmeasured 
risk factors for the outcomes in our analyses (sleep problems or mortality). We adjusted for 
several demographic and clinical risk factors, but we were not able to adjust for others such as 
benign prostatic hyperplasia, socioeconomic status, cognitive impairment, and mental-health 
status. In the analyses of mortality, unmeasured confounders may have exaggerated the 
positive associations with certain sleep problems, particularly, excessive sleep. The fact that our 
adjusted associations tended to be noticeably weaker than the corresponding crude 
associations suggests that it was not possible, with the available data, to fully control for 
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confounding. On the other hand, some covariates we adjusted for may have been mediators in 
causal pathways linking sleep problems with mortality, which could have resulted in 
underestimates of the effects of interest.  
Several unique aspects, strengths of our study, and advantages over previous NHANES 
studies of sleep problems in the US, merit attention.5,28,43 The fact that we analyzed a large, 
randomly selected, contemporary, representative sample of the US population of persons with 
and without CKD from several biennial surveys, the use of sampling weights to reflect the 
complex survey designs, and the use of comparable data collection methods across surveys 
enhanced our ability to make reliable statistical inferences about the US adult population. We 
measured 5 sleep problems, a composite sleep-problem index, and 4 complementary measures 
of CKD;5,28 we adjusted for several potential confounders; we used a state-of-the-art method, 
multiple imputation, to handle missing data—all of which helped to enhance causal inference.   
In conclusion, the relatively high prevalence of sleep problems among persons with CKD 
in the US and the associations of those sleep problems with mortality underscore their 
potential clinical importance of addressing this topic by both primary care providers as well as  
by specialists. Future work could address the feasibility of early identification, objective 
characterization and management of sleep problems among patients with CKD and ESRD and 
studying the effects of those proactive practices on patient health, disease progression and 
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Tables and figures 
Table 2.1: Summary statistics—weighted proportion (%) or weighted mean (and standard deviation)—





(n = 27,365) 
No CKD 
(n = 22,137) 
CKD 
(n = 5,228) 
Age (years) 47 (0.27) 45 (0.24) 60 (0.39) 
     20-34 (%) 28 31 12 
     35-49 (%) 29 31 17 
     50-64 (%) 26 26 23 
     65-74 (%) 10 8 19 
     >75(%) 7 4 29 
Male (%) 48  49  42  
Race/ethnicity (%)    
     Hispanic 14  14  11  
     Non-Hispanic White 68  68  70  
     Non-Hispanic Black 11  11  13  
     Other non-Hispanic race 7  7  6  
Body Mass Index (kg/m2) 28.8 (0.08) 28.6 (0.09) 29.9 (0.14) 
     <18.5 Underweight (%) 3 2 2 
     18.5 to <25 normal weight 
(%) 
29 30 25 
     25 to <30 overweight (%) 33 34 30 
     ≥30 obese (%) 35 34 43 
Diabetes (%) 11  7  28 
Hypertension (%)  34  27  71  
Smoking (%) 33  33  33  
Cancer (%) 10  8 17  
Cardiovascular disease (%) 8  6  24  
Chronic respiratory disease (%) 18  18  21  
Full time job 38  38 37 
Worsening confusion or 
memory loss in the past 12 
monthsa 
15 12 21 




Table 2.2: Estimated cross-sectional association (adjusteda odds ratio and 95% CI) between each CKD 
measure and each binary sleep problem (outcome) in 2005-14 for the total study population  
 
CKD Measure 











CKD status      
     No CKD (ref.) 1 1 1 1 1 










     P-value  0.037 0.78 <0.001 0.29 <0.001 
 
ACR category 
     
     ACR<30 (ref.) 1 1 1 1 1 
     30≤ACR≤300 0.89 



















    P for trendd 0.65 0.11 <0.001 0.16 <0.001 
 
eGFR category 
     
     eGFR≥60 (ref.) 1 1 1 1 1 
     30≤eGFR<60 0.82  



















    P for trende 0.26 0.68 <0.001 0.003 <0.001 
 
CKD prognostic category 
 
 
   
     Low  (ref.) 1 1 1 1 1 
     Moderate 































    P for trendf 0.19 0.52 <0.001 0.18 <0.001 
aAdjusted for survey year, age, sex, and race/ethnicity, diabetes, hypertension, obesity, and medications 
that affect drowsiness and cognition (sedatives, stimulants, and other drugs).  
bUsing weighted ordinary binary logistic regression.  
cUsing weighted multinomial logistic regression, where inadequate sleep (<7 hours/night) and excessive 
sleep (>9  hours/night) are compared with recommended sleep (7-9 hours/night).  
dACR category were considered as an interval variable (1-3) to test for a monotonic trend.  
eeGFR categories were considered as an interval variable (1-3) to test for a monotonic trend.  
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fCKD prognostic category were considered as an interval variable (1-4) to test for a monotonic trend.  
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Table 2.3: Weighted prevalence (%) of each binary sleep problem and category of the sleep-problem 









Trouble sleeping 25.9  25.2  30.0 
Sleep disorder 8.5  7.9  11.6 
Nocturia 24.3  21.4  40.3 
Inadequate sleep 
 
36.5  36.7  35.5 
Excessive sleep 
 
2.4  1.9  5.0 
Sleep-problem index scorea      
  0 39.0  40.6  30.1 
  1 36.2  36.2  36.4 
  2-4 24.8  23.2  33.5 
aSleep-problem index was created by summing the number of problems (trouble sleeping, sleep 
















Table 2.4: Estimated association (crude and adjusteda hazard ratios [HR] and 95% CI) between each 
sleep problem and all-cause mortality, by CKD status; total study population, 2005-14 
 




















HR (95% CI) 












































Sleep duration         



















        Recommended 1 1  1 1  1 1 















aAdjusted for survey year, age, sex, and race/ethnicity, diabetes, hypertension, obesity, smoking, 
cardiovascular disease, chronic respiratory disease, cancer, other sleep problems, and medications that 
affect drowsiness and cognition (sedatives, stimulants, and other drugs). Additional adjustment of CKD 






Table 2.5: Estimated associations (crude and adjusteda hazard ratios [HR] and 95% CI) of excessive 
sleep and category of the sleep-problem index score with all-cause mortality, by CKD status; total 
study population, 2005-14 
 


































Sleep-problem index scorec       




































P for trendd <0.0001 0.01  <0.0001 0.11  <0.0001 0.018 
aSleep-problem index was created by summing the number of problems (trouble sleeping, sleep 
disorder, nocturia, inadequate sleep) reported by each subject. 
bAdjusted for survey year, age, sex, and race/ethnicity, diabetes, hypertension, obesity, smoking 
cardiovascular disease, chronic respiratory disease, cancer, sleep problem index, and medications that 
affect drowsiness (sedatives, stimulants, and other drugs)  . Additional adjustment of CKD status for the 
analysis for all.  
cAdjusted for excessive sleep, survey year, age, sex, and race/ethnicity, diabetes, hypertension, obesity, 
smoking, cardiovascular disease, chronic respiratory disease, and cancer. Additional adjustment of CKD 
status for the analysis for all.   





Table 2.6: Estimated association (crude and adjusteda hazard ratios and 95% CI) between each sleep 
problem and all-cause mortality, overall and by CKD status in 2005-14 for the total study population: 
Sensitivity analysis of all participants in the study population where follow-up is limited to 1 year. 
 






































































Sleep duration         




















        Recommended 1 1  1 1  1 1 
















aAdjusted for survey year, age, sex, and race/ethnicity, diabetes, hypertension, obesity, smoking, other 
sleep problems, cardiovascular disease, chronic respiratory disease, cancer, and medications that affect 
drowsiness and cognition (sedatives, stimulants, and other drugs). Additional adjustment of CKD status 




Figure 2.1: Trend in the standardizeda prevalence (%) of each sleep problem and sleep-problem indexb 
(Figs 1.a-g) in 2005-14 for the total study population, by NHANESc survey years and CKD 
 




























c) Nocturia (%) 
 
 

























































e) Excessive sleep (% >9 hours/night) 
 
 
  f) Sleep-problem index score>1 (%) 
 
 





































bThe sleep-problem index ranging from 0 (no problems) to 4, was created by summing the number of 
problems (trouble sleeping, sleep disorder, nocturia, inadequate sleep) reported by each subject. 






Table 2.A1: List of medications that affect drowsiness and cognition included in the study 
Drug category Drug name 
Sedatives BETA-ADRENERGIC BLOCKING AGENTS – 
UNSPECIFIED 
 ANXIOLYTICS, SEDATIVES, AND HYPNOTICS – 
UNSPECIFIED  
 MUSCLE RELAXANTS – UNSPECIFIED  
 ANTIHISTAMINES – UNSPECIFIED  
 ANTIDEPRESSANTS – UNSPECIFIED  
 ANTIPSYCHOTICS – UNSPECIFIED  
 OPHTHALMIC ANTIHISTAMINES AND 
DECONGESTANTS – UNSPECIFIED  
 ATENOLOL  
 CARBAMAZEPINE  
 VALPROIC ACID 
 METOPROLOL  
 PHENYTOIN  
DIPHENHYDRAMINE  
 GABAPENTIN 





























DOXYLAMINE; PYRIDOXINE  
















FLUOXETINE; OLANZAPINE  
METHYLPHENIDATE  
PAROXETINE  















Table 2.A2: Number of participants, by joint and marginal categories of eGFR and 
albuminuria; total study population, 2005-14.  
 
Total population 
Categories of eGFR 
(mL/min/1.73 m2) 
Categories of Albuminuria (mg/g) 
Total <30 30-300 >300 
≥90 14789 1299 247 16335 
60-89 7006 964 236 8206 
45-59 1014 299 108 1421 
30-44 303 197 89 589 
15-29 54 49 60 163 
<15 4 7 32 43 
Total 23170 2815 772 26757 
* CKD prognosis cells: white, low risk; light gray, moderate risk; medium gray, high risk; dark gray, very 
high risk.13   
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Table 2.A3: Standardizeda prevalence (%) of each sleep problem and sleep-problem indexb, by 




Trouble sleeping (%) 
 
Sleep disorder (%) 
All CKD No CKD All CKD No CKD 
2005-2006 24.1 24.2 24.2  7.4 8.8 7.3 
2007-2008 24.0 27.2 23.5  7.6 10.3 7.3 
2009-2010 25.0 29.9 24.3  7.1 10.5 6.8 
2011-2012 26.5 25.9 26.8  8.9 13.5 8.3 
2013-2014 27.7 32.1 26.9  10.2 15.0 9.5 
P for trend  <0.001 0.005 0.012  <0.001 0.001 <0.001 
 
Year Inadequate sleep: <7 hours (%)  Excessive sleep: >9 hours (%) 






2005-2006 35.9 40.3 35.2  2.6 2.9 2.2 
2007-2008 38.3 39.9 38.1  2.3 3.5 1.8 
2009-2010 36.6 40.2 36.1  2.2 3.1 1.8 
2011-2012 37.0 35.4 37.4  2.2 3.3 1.7 
2013-2014 35.4 39.4 34.7  2.8 3.2 2.4 
P for trend  0.53 0.68 0.35  0.79 0.72 0.92 
                            







2005-2006 24.2 32.8 22.6 
2007-2008 24.3 30.7 23.2 
2009-2010 24.0 32.9 22.6 
2011-2012 24.1 32.1 22.8 
P for trend  0.45 0.65 0.11 
 
aStandardized for age and sex. Using 2000 US Census population as the standard population. 
Year Sleep-problem index score>1 (%)  
All CKD No CKD 
2005-2006 23.0 27.6 22.2  
2007-2008 23.8 29.8 22.8  
2009-2010 24.2 32.0 23.1  
2011-2012 24.8 30.1 24.1  
2013-2014 25.7 32.9 24.4  
P for trend  0.036 0.068 0.056  
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bSleep-problem index was created by summing the number of problems (trouble sleeping, sleep 
disorder, nocturia, inadequate sleep) reported by each subjects. 
cCKD, chronic kidney disease; as reduced kidney function (estimated glomerular filtration rate [eGFR] < 
60mL/min/1.73m2, calculated with the CKD-EPI equation13 and/or the presence of albuminuria (urine 
albumin-to-creatinine ratio [ACR] ≥30 gm/g, standardized to the 2005-06 cohort. 
Table A4 
 
Table 2.A4: Weighted prevalence (% and 95% CIa) of each sleep problem, by category of CKD 




























































Table 2.A5: Crude prevalence (% and 95% CI) of each sleep problem (a-e), by joint and 
marginal categories of eGFR and albuminuria; total study population, 2005-14.  
 
a. Ever told a doctor of having trouble sleeping 
Categories of eGFR 
(mL/min/1.73 m2) 
Categories of Albuminuria (mg/g) 
Total <30 30-300 >300 
≥90 23.0 (21.9, 24.1) 27.3 (23.3, 31.3) 36.0 (23.4, 48.7) 23.5 (22.5, 24.6) 
60-89 29.1 (27.6, 30.6) 29.0 (24.5, 33.6) 38.5 (28.8, 48.2) 29.4 (26.7, 32.1) 
45-59 31.2 (27.5, 35.0) 35.7 (26.4, 45.0) 37.0 (20.1, 54.0) 31.5 (26.9, 36.2) 
30-44 35.9 (30.2, 41.7) 28.6 (19.1, 38.0) 28.2 (15.9, 41.4) 32.6 (27.1, 38.1) 
15-29 37.6 (22.1, 53.2) 41.0 (22.8, 59.2) 42.2 (25.8, 58.8) 39.9 (29.5, 50.4) 
<15 28.1 (0, 72.1) 75.0 (35.4, 100) 40.5 (20.8, 60.3) 49.94 (25.7, 74.1) 













b.  Even been told by a doctor of having sleep disorder 
Categories of eGFR 
(mL/min/1.73 m2) 
Categories of Albuminuria (mg/g) 
Total <30 30-300 >300 
≥90 6.9 (6.4, 7.5) 10.4 (7.7, 13.0) 14.1 (5.8, 22.4) 7.3 (6.8, 7.9) 
60-89 8.7 (8.7, 10.6) 14.1 (10.9, 17.3) 13.5 (6.1, 20.8) 10.0 (8.4, 11.7) 
45-59 10.3 (7.3, 13.3) 13.5 (7.3, 19.6) 15.6 (1.9, 29.2) 11.0 (7.7, 14.3) 
30-44 12.2 (7.6, 16.9) 14.5 (5.9, 23.1) 21.4 (7.8, 35.0) 13.4 (9.4, 17.5) 
15-29 20.7 (7.6, 33.8) 15.3 (3.7, 26.8) 13.9 (0.44, 27.4) 15.7 (9.5, 21.9) 
<15 28.1 (0, 77.1) 0 13.0 (0, 26.5) 12.1 (2.5, 21.5) 





c.  Nocturia 
Categories of eGFR 
(mL/min/1.73 m2) 
Categories of Albuminuria (mg/g) 
Total <30 30-300 >300 
≥90 18.9 (16.6., 21.1) 28.7 (24.4, 33.0) 42.9 (31.8, 53.9) 20.8 (18.0, 22.4) 
60-89 25.5 (22.5, 28.4) 43.4 (37.2, 49.5) 47.5 (36.4, 58.7) 27.8 (24.0, 31.6) 
45-59 40.7 (35.6, 45.8) 48.1 (39.0, 57.2) 59.6 (43.1, 76.0) 42.7 (37.0, 48.5) 
30-44 50.6 (40.8, 60.3) 54.1 (43.9, 64.4) 65.2 (45.0, 85.3) 52.8 (44.1, 61.6) 
15-29 50.2 (34.5, 66.0) 64.8 (45.8, 83.8) 66.4 (46.4, 86.3) 61.1 (49.2, 73.0) 
<15 55.6 (0, 100) 15.6 (0, 53.4) 77.4 (52.3, 100) 57.3 (30.2, 84.4) 






d.  Inadequate sleep (<7 hours) 
Categories of eGFR 
(mL/min/1.73 m2) 
Categories of Albuminuria (mg/g) 
Total <30 30-300 >300 
≥90 38.0 (35.5, 39.4) 42.1 (38.9, 45.3) 43.9 (39.2, 48.7) 38.3 (37.0, 39.7) 
60-89 34.2 (32.7, 35.7) 36.2 (31.9, 40.5) 39.4 (33.5, 45.3) 34.5 (33.0, 35.9) 
45-59 27.9 (24.1, 31.7) 34.3 (27.1, 41.4) 38.0 (27.6, 48.4) 29.6 (26.1, 33.1) 
30-44 27.4 (22.8, 32.0) 25.3 (19.4, 31.2) 46.7 (34.5, 58.9) 29.4 (25.7, 33.1) 
15-29 23.7 (13.9, 33.6) 29.0 (18.8, 39.0) 36.5 (25.5, 47.4) 30.0 (23.6, 36.4) 
<15 33.8 (21.3, 42.3) 59.9 (34.4, 85.3) 48.0 (33.4, 62.7) 49.6 (33.8, 65.4) 





e.  Excessive sleep (>9 hours) 
Categories of eGFR 
(mL/min/1.73 m2) 
Categories of Albuminuria (mg/g) 
Total <30 30-300 >300 
≥90 2.0 (1.7, 2.2) 2.0 (1.0, 2.9) 3.5 (0.7, 6.3) 2.1 (1.8, 2.3) 
60-89 1.7 (1.4, 2.0) 5.0 (3.3, 6.7) 6.4 (0.0, 13.3) 2.2 (1.5, 2.8) 
45-59 4.4 (2.8, 5.9) 5.9 (3.1, 8.7) 3.9 (0.0, 8.3) 5.1 (3.6, 6.7) 
30-44 8.8 (4.6, 13.0) 11.4 (0.5, 22.1) 1.4 (0.0, 3.4) 9.7 (6.7, 12.6) 
15-29 10.8 (1.0, 20.5) 11.3 (0.5, 22.1) 21.0 (8.1, 33.9) 14.1 (7.9, 20.3) 
<15 44.4 (0, 100) 0 6.2 (0, 18.8) 8.6 (0, 18.9) 
Total 2.1 (1.9, 2.3) 4.3 (3.2, 5.3) 7.2 (4.3, 10.1) 2.5 (2.1, 2.6) 



















Aim 2: Point and Period Prevalence of Obstructive Sleep Apnea (OSA) Among U.S. Veterans 
With and Without Chronic Kidney Disease (CKD) 
Abstract   
 
Background: To better understand the population burden of obstructive sleep apnea (OSA) and 
its relation with chronic kidney disease (CKD) and its risk factors, we conducted a large 
retrospective cross-sectional study of OSA in U.S. veterans who sought care in Veteran 
Administration facilities in fiscal year (FY) 2018. 
Methods: Using data from 6.2 million veterans for FY2014-18, we estimated OSA point 
prevalence (P) at the last visit to a VA facility in FY2018 (index date T) and complementary 
period prevalence (PP) of OSA before time T as far back as the start of FY2014, stratified by CKD 
status in FY2018. PP for each duration was estimated using a method that takes into account 
left censoring of veterans followed back for different durations (analogous to the Kaplan-Meier 
method for dealing with right censoring in a cohort or randomized study). To examine 
associations, modified Poisson regression was used to estimate point-prevalence ratios (PR), 
and Cox regression was used to estimate period-prevalence ratios (PPR). The effects of age, sex, 




Results: At time T, the P of OSA was 24.9% in veterans with CKD (14.8% of the study 
population), 15.2% in those without CKD, and 16.6% in the total study population. The 12-and 
60-month PPs were 3.5% and 15.0%, respectively, in veterans with CKD, 2.8% and 11.0% in 
those without CKD, and 2.9% and 11.6% in the total population. Widths of all 95% confidence 
intervals (CI) were very narrow (<0.2%). The 60-month PP was positively associated with CKD 
(adjusted 60-month PPR = 1.2; 95% CI: 1.2-1.2), obesity (2.2; 2.2-2.3), being male (1.8; 1.7-2.0), 
having hypertension (1.3; 1.3-1.3) or diabetes (1.4; 1.3-1.4), and inversely associated with age 
≥65 vs. <45 (0.80; 0.80-0.81). The associations of PP with sex were stronger for veterans 
without CKD than for those with CKD; and there was little association with race/ethnicity, 
except being less prevalent in other races than in non-Hispanic Whites. Associations of OSA 
with CKD and all covariates were stronger for P at time T than for 60-month PP.   
Conclusion: The population burden of OSA, reflecting both point prevalence at time T and 
period prevalence before T, is quite high in U.S. veterans, especially among men with CKD. 
These findings, along with the associations of CKD risk factors with OSA, should be of potential 





Obstructive sleep apnea (OSA) is one of the most common sleep disorders,1 causing 
repetitive cessation of breathing while a person is sleeping, in both the general U.S. population 
as well as in the military and veteran populations.2 The prevalence of OSA in the U.S. population 
was found to be 9% for women and 24% for men, and the prevalence of the OSA syndrome 
(combined with daytime hypersomnolence) was 2% for women and 4% for men.3 OSA has been 
associated with depression, hypertension, diabetes, cardiovascular disease, and mortality.4,5,6 A 
recent meta-analysis of 12 studies showed that the hazard ratio (HR) of all-cause mortality was 
1.26 (95% CI: 1.09, 1.43) for persons with OSA compared to those without OSA. The association 
was stronger for persons with severe OSA (HR = 1.60; 95% CI: 1.30, 1.90).4  
Chronic Kidney Disease (CKD), a common disorder worldwide with a prevalence of 
14.8% in the U.S. population,7 is currently defined by abnormal kidney function (estimated 
glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 or kidney damage (albuminuria indicated 
by albumin-to-creatinine ratio ≥ 30 mg/g) over three months. CKD progression is thought to 
result in the development of OSA through chemoreflex responsiveness, pharyngeal narrowing, 
and accumulation of uremic toxins.8,9 However, unlike the effect of CKD on cardiovascular 
morbidity and mortality, the hypothesized effect of CKD on OSA risk is not fully understood. 
Veterans are more vulnerable to sleep disturbance because of the high prevalence of 
possible risk factors including obesity, male sex, hypertension, depression, posttraumatic stress 
disorder, depression, substance use, and other comorbidities comparing to the general 
population.10,11,12,13 Of the 21 million veterans in the U.S., about 9 million receive healthcare 
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each year from the Veterans Health Administration (VHA) system, America’s largest integrated 
health care system.14,15 
Although the incidence of a disease is more fundamental than prevalence for 
understanding risk-factor effects on disease (etiology), the burden of a disease in a 
population—with respect to the need or demand for healthcare and patient needs—is largely a 
function of prevalence, which can be measured in two ways.16 The measure most commonly 
used in epidemiologic research and population surveillance is technically “point prevalence,” 
meaning the proportion of a population that has the disease at one time t, where t may vary 
among individuals by age, calendar time, or birth year (e.g., persons ages 18-29, who are 
surveyed between January 1, 2015 and December 31, 2017). The other prevalence measure, 
“period prevalence,” is infrequently used to study disease but often used to study behavioral 
outcomes such as drug or service use, based on self-reports or records. 17 Although period 
prevalence can be defined in different ways, here we mean the proportion of persons observed 
at time t, who had the disease any time during a previous period extending as far back in time 
to t0, which may be defined from the person’s perspective (age) or the population perspective 
(calendar time). Thus, the numerator in period prevalence may include persons who became 
cases during the period, t0 to t, i.e., incident cases of the disease, and it may include previous 
cases of the disease who recovered before time t. Despite its infrequent use in contemporary 
epidemiology, period prevalence can be useful in planning service delivery systems, especially 
for remittent or episodic conditions such as OSA. 
However, there is a dearth of research accurately estimating prevalence of sleep apnea 
among the veteran population. Different methods were used to estimate prevalence of sleep 
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apnea so prevalence of sleep apnea might not be comparable.18,19 Limited studies have 
addressed the importance of sleep apnea prevalence in veterans with CKD versus veterans 
without CKD using relatively small sample sizes or selected study populations.20 Therefore, our 
study aims were to use data in the U.S. VHA facilities to estimate the point and period 
prevalence of OSA among non-CKD and CKD population by using a method that takes into 
account left censoring of veterans followed back for different durations. Finally, we evaluated 
the associations between selected covariates and prevalence of OSA among non-CKD and CKD 
populations.  
Methods 
Source population and study design 
This study was deemed “non-regulated” by the Institutional Review Board at the 
University of Michigan, as VHA system provides de-identified data as part of the Centers for 
Disease Control and Prevention’s CKD Surveillance System Contract with the University of 
Michigan. The VHA system is the nation's largest integrated health care system, which contains 
an abundance of health information of veterans followed longitudinally.21 Veterans Health 
Information Systems and Technology Architecture (VistA) includes the VA’s electronic health 
records. From VistA, National Data Systems makes the extracts available and turns them into 
Medical SAS datasets (MedSAS). Inpatient, Outpatient, Lab, and Pharmacy electronic medical 
records were accessed from MedSAS Dataset and Department of VA Corporate Data 
Warehouse files using the U.S. Veterans Administration Informatics and Computing 
Infrastructure (VINCI) system.22  
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The study is a retrospective cross-sectional study of eligible U.S. veterans. Patients were 
included in the study if they sought care in the VA medical system in FY2018, had information 
on date of birth, and were at least 18 year-old at index time T, which was defined as the last 
visit to a VHA facility in FY2018. Theses selected participants at index time T were followed back 
in time to as early as the start of FY2014 for obtaining outcome information on OSA diagnosis. 
Period prevalence (PP) for a period of duration ∆ (in months)—Δ PP—is defined retrospectively 
going back in from time T to a previous month as far back as the start of FY2014. The major 
challenge is dealing with left censoring40 of study veterans when going back in time, i.e., not all 
veterans will be available as far back as the start of FY2014; many would not have used VA 
facilities throughout the 60-month study period. The final study population at time T contained 
6.2 million participants.  
Study variables 
Outcome: OSA 
De-identified inpatients and outpatients with OSA diagnoses were extracted from 
MedSAS databases.  Prevalent OSA was based on multiple ICD-9-CM or ICD-10-CM codes 
related to OSA and CPT code for continuous positive airway pressure (CPAP) treatment (see 
Table 1 for codes) during the study period (FY2014-FY2018). “New” point-prevalent OSA cases 
were identified retrospectively, going back in time from index time T. After excluding point-
prevalent OSA cases at time T, “new” period-prevalent cases were identified each month, 
starting one month before T, that were not previously identified in a more recent month (closer 
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to T). Therefore, the cumulative number of PP OSA cases increases as case detection proceeds 
back in time (analogous to cumulative incidence in a cohort study). 
CKD status 
De-identified inpatients and outpatients with CKD diagnoses were extracted from 
MedSAS databases. CKD prevalence at index time T was based on the presence of at least one 
of three criteria: having a diagnosis of ICD-9 or ICD-10 CKD (see Table 1 for codes); an eGFR <60 
ml/min/1.73 m2, using the CKD-EPI formula; and the presence of albuminuria (urine albumin-to-
creatinine ratio [UACR] ≥30 mg/g).23  
Covariates 
Data for measuring covariates at index time T were retrieved from MedSAS and CDW 
databases and included date of birth, date of last VA visit in FY2018, sex, race/ethnicity, height 
and weight (average of last two values), diabetes status and hypertension status (see codes in 
Table 1). Race/ethnicity was classified as Hispanic (any race), non-Hispanic white, non-Hispanic 
black, or other non-Hispanic race (American Indian/Alaska Native, Asian, Native 
Hawaiian/Pacific Islander, and other). Obesity was defined as a body mass index (BMI) ≥30 
kg/m.2   
Statistical analysis 
Descriptive statistics are reported as percentages for categorical variables and as means and 
standard deviations (SD) for continuous variables stratified by CKD status. All point- and period-
prevalence estimates are expressed as percentages.  
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Estimating point prevalence and period prevalence of OSA 
Point prevalence (P) was defined as the proportion of people with an OSA diagnosis at 
index time T in the total study population. To handle left censoring in the estimation of period 
prevalence (PP), we used McFarland’s method, which was devised for drug use or service 
utilization derived from administrative data (more details in the next paragraph and Appendix 
A).17 ∆ was defined as the period (in months) prior to index time T. McFarland’s method was 
used to estimate the Δ period prevalence (∆ PP) in monthly (and 6-month) intervals going back 
in time from T−1 (1 month before index time T) to time t among noncases of OSA at time T, to 
be called the restricted study population. McFarland’s method cannot be applied to the 
inclusion of point-prevalent cases at time T; analogously, the Kaplan-Meier method is not 
applied to the inclusion of point-prevalent cases in a cohort study of disease incidence.17 
McFarland’s method applied to cross-sectional data is thus like doing a survival analysis in 
reverse, going back in time instead of forward to handle right censoring in a cohort study or 
randomized trial. McFarland’s method was used to estimate the PP at each month from T-1 (1 
month before T) to T-60 (the start FY2014). The PP at each month from T-1 to T-60 is shown in 
Figs 1-3 (which is based on the monthly accumulation of PP cases). Only Tables 3-4 present 
tabular displays of PP at 6-month intervals. 
However, our study differed from the example provided in McFarland’s article17 in two 
related ways. First, the outcome of McFarland’s study was drug use, which would not be 
measured as point prevalence at index time T whereas our outcome was a chronic condition 
that was present in many subjects at index time T. The method was created to estimate the PP 
of drug use during a previous period among survey respondents for whom point prevalence 
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was not of interest (unlike a chronic condition). Furthermore, while we were interested in 
estimating associations with PP (i.e., to obtain period prevalence ratios [PPR], McFarland’s 
method was limited to the estimation of PPs for different periods or groups without computing 
measures of association adjusted for potential confounders. Therefore, the differences 
described above required that we modify McFarland’s method slightly and extend his method 
to estimate ratio measures of associations. 
As a secondary objective, we compared McFarland’s method with a simpler approach 
(naïve method) for estimating PP without taking left censoring into account. With this naïve 
method, the estimated Δ PP of OSA in the restricted study population is the proportion of all 
persons who were found to have a diagnosis of OSA between time T−1 and previous time t (i.e., 
again excluding point-prevalent cases at index time T from the numerator and denominator).  
Estimating associations with point- and period-prevalence ratio 
Modified Poisson regression24 was used to estimate point prevalence ratios (PR and 95% 
CIs) for crude and adjusted associations between individual-level factors and OSA point 
prevalence at index time T, by CKD status.  To estimate crude and adjusted associations of 
those same factors with period-prevalence, we extended McFarland’s method using Cox 
regression to estimate 60-month period-prevalence ratios (PPR and 95% CI) in the restricted 
study population. To adjust for potential confounders in both analyses, but not mediators, we 
used the causal diagram (directed acyclic graph) in Figure 1 to guide the analysis of each 
exposure including CKD.  
Percentage of left censoring  
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To quantify the effective difference between McFarland’s method and the naïve method 
for estimating OSA PP, we quantified the relative amount of left censoring used in the 
estimation of the 60-month PP and determined the number and proportion of person-days 
reduced by left censoring in McFarland’s method for estimating the Δ PP of OSA in the 
restricted study population. This was done by comparing person-days of follow-back using 
McFarland’s method with person-days of follow-back using the naïve method (involving no left 
censoring). The difference percentage is shown as the percentage of person-days of follow-back 
lost to left censoring using McFarland’s method to estimate the Δ PP of OSA among U.S. 
veterans, by CKD status and 12-month interval prior to index time T (details are shown in 
Appendix B).  
Sensitivity analyses 
Because McFarland17 did not use his method to model associations with PP, we did a 
sensitivity analysis to assess the validity of our approach applying Cox regression to estimate 
crude 60-month PP ratios for each predictor in our main analysis. The model-based PPR for 
each predictor (e.g., sex) was compared with the corresponding crude 60-month PPR computed 
manually by taking the ratio of PP, using McFarland’s method, for the exposed group versus the 
unexposed group (e.g., men versus women). 
All analyses were performed in SAS version 9.2 and 9.4.  
Results 
Table 2 shows summary statistics (mean and standard deviation [SD] or percentage) for 
selected baseline variables, by binary CKD status, in the total study population of 6,220,481 
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participants (last visit in FY2018). The mean age was 61 years, 88% were male, 62% were non-
Hispanic Whites, and 15% were patients with CKD. Compared to participants without CKD, 
those with CKD were more likely to be older, male, non-Hispanic White, obese, have diabetes 
and hypertension. 
Point prevalence (P) of OSA at index time T of the total study population of 6.2 million 
veterans was 16.6% (Table 3). It was higher among 5.3 million veterans with CKD (24.9%) than 
among 0.9 million without CKD (16.6%).  As shown in Table 4, the total number of prevalent 
cases of OSA in the study population was about 1.5 million, of which 1.0 million (67.4%) were 
point-prevalent cases identified at time T and 0.5 million (32.6%) were additional period-
prevalent cases identified in the 5-year period before T (FY2014-18).  
Table 5 and Figure 2 present the period prevalence of OSA (∆-month PP [%] and 95% CI) 
in 6-month intervals, by CKD status, using McFarland’s method among all noncases of OSA 
observed at time T. The ∆ PP of OSA in the total group increased from 0.04% after 6 months to 
11.6% after 60 months. The 60-month PP of OSA was higher in veterans with CKD (15.0%; 95% 
CI: 14.9%, 15.1%) than in those without CKD (11.0%; 95% CI: 11.0%, 11.0%). As shown in Figure 
2 (as well as Figures 3-4), there was a sudden increase in the Δ PP every 12 months, which may 
be explained by increased visits to VA facilities or enhanced documentation of OSA in the 
medical records at the end of each FY.  
Table 6 and Figure 3 show the Δ period prevalence of OSA, by CKD status, using the 
naive method of PP estimation (ignoring left censoring). The ∆ PP of OSA in the total group 
increased from 0.04% after 6 months to 10.0% after 60 months (Table 6). The overall pattern of 
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estimated PP, by CKD status, was similar with the naïve method as it was with McFarland’s 
method (Figure 4), but the naïve estimates were slightly lower. For example, the 60-month PP 
of OSA was 1.6% lower in the total group, 0.9% lower in CKD group, and 1.6% lower in the non-
CKD group (Tables 5-6). Although there seemed to be little bias in the naïve method, relative to 
McFarland’s method, we wanted to quantify the amount of left censoring due to the absence of 
visits to VA facilities in the months prior to time T, due either to pre-veteran status or lack of VA 
utilization among veterans (see Appendix B). As shown in Table 7, 76.3% of all follow-back time 
using McFarland’s method was due to left censoring of noncases (analogous to right censoring 
in a cohort study), and most of the follow-back more than 2-3 years before index time T was 
attributable to left censoring, which makes those estimates of PP much less informative. Yet 
the addition of all that follow-back time in the naïve method, which was greater in veterans 
with CKD, resulted in little overall bias in the estimation of PP (Figure 4).   
Crude and adjusted prevalence ratios (PR and 95% CI) between selected covariates and 
OSA point prevalence in the total study population at time T, by CKD status, are shown in Table 
8. Each covariate is adjusted for potential confounders, but not mediators, as implied by the 
DAG in Figure 1. The point prevalence of OSA at index time T was positively associated with 
being male (adjusted PR = 1.8), Black versus White (1.1), Hispanic versus White (1.2), obese 
versus non-obese (2.3), having diabetes (1.4), hypertension (1.5), and CKD (1.2), and having an 
inverted U-shaped association with age. The positive associations with sex, obesity, diabetes, 
and hypertension were stronger in veterans without CKD group than in those with CKD.  
Crude and adjusted associations of the same covariates with OSA period prevalence 
using McFarland’s method are shown in Table 9. The adjusted results are similar to those found 
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for point prevalence at time T, except the latter associations tend to be a little weaker (PPRs 
closer to 1), especially for male sex (PPR = 1.4 vs. PR = 1.8). The strongest association observed 
in both analyses was with obesity; the adjusted PPR in the total restricted study population was 
2.1 (95% CI: 2.1, 2.1). The adjusted associations with period prevalence were mostly similar for 
veterans with and without CKD, except associations for three variables that were stronger in 
persons without CKD: male sex (adjusted PPR = 1.5 vs. 1.1), other non-Hispanic race versus 
whites (0.71 vs. 0.84), and age ≥65 versus <45 (0.74 vs. 0.83). 
Results of the sensitivity analysis to check the validity of using Cox regression to 
estimated PPRs for each covariate are shown in Table 10. The crude PPR for each covariate 
using Cox regression was very similar to the PP ratio manually calculated from separate PPs 
using McFarland's method. These findings suggest that our use of Cox regression yielded 
reasonably valid results, at least for crude period-prevalence ratios. 
Discussion 
Our study was conducted among 6.2 million adult veterans nationwide with extensive 
claims data from FY2014-2018, which allowed us to estimate the ∆ PP of OSA by both 
McFarland’s method and naïve method, stratified by CKD status. In addition, we measured the 
associations between selected variables and prevalence of OSA. We observed slightly higher ∆ 
PP of OSA estimated by McFarland’s method than by the naïve method, which reflects artificial 
enlargement of denominators in the naive method.  The ∆ PP of OSA was greater for adults 
with CKD than for those without CKD. The prevalence of OSA was positively associated with 
being male, being black, being Hispanic, being obese, having diabetes, having hypertension, and 
having CKD, but inversely associated with age especially for CKD group. These findings highlight 
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the importance of paying attention to the potential presence of sleep problems among 
veterans, both in those with CKD and without CKD both by primary care and by specialist 
providers. 
 Our study showed that non-Hispanic Blacks and Hispanics had higher prevalences of 
OSA comparing to non-Hispanic Whites. On the other hand, other race/ethnicity except for 
Blacks and Hispanics had lower prevalence of OSA comparing to non-Hispanic Whites. Increased 
prevalence of OSA in non-Hispanic Black and Hispanic was also reported in Ramos et al,25 
different characteristics of OSA patients, such as more likely to be obese, hypertensive, and 
diabetic, were shown in Blacks and Hispanics comparing to their White counterparts.26,27 A 
review paper showed similar results that OSA prevalence was increased among African 
Americans, Native Americans, and Hispanics, whereas the prevalence of OSA in Asians and 
Asian Americans remained similar or lower than in Whites.28 In contrast, a recent review paper 
did not see the racial disparity in OSA in 17 articles after adjusting for variables such as obesity, 
comorbidities and socioeconomic status (SES).29 These findings indicate that dissimilar OSA 
prevalence in different racial and ethnicity groups may due to difference in susceptibility of 
OSA, distribution of risk factors including comorbidities, OSA severity, and sleep apnea 
phenotypes among different racial and ethnicity groups. Furthermore, these risk factors (e.g., 
obesity, certain comorbidities, and SES) could be influenced by race/ethnicity, suggesting they 
are mediators rather than confounders. Of course, distinguishing between confounders and 
mediators with race effects is not straightforward. We addressed this issue in Aim 3. 
 Our study consisted of 88% of male participants, who had a higher prevalence of OSA 
than did females. Male gender has been thought to be a risk factor for OSA.30 However, the 
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difference of the OSA prevalence between males and females decreases when women become 
pregnant or reach menopause.31 This reduction in OSA prevalence could result from aging, 
physiological changes including fat mass distribution, sex hormones and upper-airway 
collapsibility in women.32 We also observed this decline in the difference of OSA prevalence 
among males and females who were 65 and older (male: 20.2%; female: 17.1%) vs. who were 
45-64 (male: 29.1%; female: 18.4%) (data not show). 
The high prevalence of obesity may lead to the increased incidence and prevalence of 
OSA among veterans, especially among those with CKD. Obesity was the strongest predictor of 
OSA prevalence in our analyses (PR=2.1 and PPR=2.4).  Large cohort studies have shown a 
monotonic association between elevated BMI and the prevalence of OSA.33,34,35 In the 
Wisconsin Sleep Cohort study, a 10% weight gain predicted a 32% increase in the apnea-
hypopnea index (AHI), whereas a 10% weight loss predicted a 26% decrease in the AHI.33 
Additionally, in the Cleveland Family Study, an increase of one BMI unit (kg2/wt = 1) was 
associated with a 14% increase odds of one unit increase in AHI (numbers of apneas and 
hypopneas/hour=1). However, the effect of increased BMI declined to 5% for people at age 60 
years.34 In fact, symptoms of OSA have shown to become less severe after the intervention of 
weight management among OSA patients. Even if obesity only partially accounts for the 
variance of the AHI,36 it may be the most effective treatments for male patients with moderate 
to severe OSA to reduce the severity of the symptoms through diet and exercise for weight 
loss.37  
 Only a few studies have focused on estimating the prevalence of sleep apnea on 
veterans defined by ICD codes,38,19 questionnaires,39,18,20 or polysomnography.20 The period 
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prevalence of OSA in our study ranged from 16.6% to 26.3% from FY2014-2018. Comparing to 
4.4% of diagnosed OSA period prevalence from FY2003-2005 reported by Diaz et al.,38our 
estimates exceed this number. Their study cohort only limited to older veterans (≥65 years) in 
the VHA system. Studies reported higher prevalence of OSA in groups with certain underlying 
diseases. For example, 69.2% veterans from PTSD outpatient clinic were categorized as high risk 
of OSA in participants consisting of more than 70% Hispanic.39 A sleep apnea point prevalence 
of 39% was obtained from another cohort of veterans with moderate to severe CKD.20 In our 
study, we reported a period prevalence of OSA ranged from 24.9% to 36.2%  for people with 
CKD, which is actually consistent with the previous study since participants in their study had 
moderate to severe CKD.20 These discrepancies in the prevalence of OSA among veterans could 
result from different ways for defining and measuring OSA, different types of sleep apnea 
included in the study, different study designs, different statistical methods for estimating OSA 
prevalence and their associations with possible risk factors, different demographic composition 
of the study population, different calendar periods with increasing awareness of sleep problems 
and elevated willingness to seek medical attention in recent years 
 Rassen et al.40 demonstrated different combinations of observable person-time, 
numerator, and denominator of chronic diseases could result in different estimates using both 
administrative claims data and electronic health records. Particularly, fixed lookback periods (a 
specific retrospective time period to surveil for existing disease) generate more stable 
estimates over time; however, they could contribute to lower prevalence and higher incidence 
estimates comparing to all-time lookback. These two sources of datasets are often left 
truncated and right censored, which makes it harder to decide who is and is not part of a study 
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population at a given time. Therefore, every study population could have different lengths of 
enrollment in the VHA system. In our study, we considered the start of the follow-back when a 
person was last treated in FY2018 in the VHA system; we stopped the follow-back when a 
veteran was diagnosed with OSA or when those with no OSA diagnosis were last observed back 
to the start of FY2014. We applied McFarland’s method17 to account for left censoring. As we 
expected, estimates from McFarland’s method17 were higher since the denominator was 
smaller considering the left censoring issue. One reason the cross-sectional associations 
between exposures and OSA are stronger for point prevalence than for period prevalence is 
due to possible "differential left censoring" in the PP analysis40. As we go back in time further to 
estimation PP, there is more left censoring, which may be more likely to differ between 
contrasting exposure groups. 
 We found an inverted U shape of the association between age and the prevalence of 
OSA. The same results were found in another study using VHA patients from FY2000 and FY 
2010; there was not a monotonic association between the sleep apnea prevalence and 
increased age.19 The non-monotonic association was also reported in the Sleep Heart Health 
Study of 5615 community-dwelling participants aged 40 to 98.41 A peak in the middle of 
exposure range for the prevalence of an AHI≥15 was shown around age 60 years in the study.41 
In addition, Young et al. suggested that most of the age-related prevalence increase occurs 
before age 65.13 Prevalence of a condition is determined by the incidence of the condition and 
its course among cases (influenced by both the rates of recovery and death). Future research is 
needed to determine whether the decreased or plateau prevalence of OSA among people more 
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than 65 could result from decreased incidence, increased mortality or detection bias among this 
age group. 
 Higher prevalence of OSA was observed among people with CKD compared to people 
without CKD in our study. However, patients with CKD could have a different etiology and 
clinical manifestations of OSA: OSA patients with advanced CKD tend to be less obese, report 
less frequent snoring, and more frequently experience apnea during sleep, unrefreshing sleep, 
and morning headache than persons without CKD.42,43 Therefore, the associations between 
certain CKD risk factors (older age, male sex, obesity) and the risk of OSA were weak in patients 
with ESRD in spite of these major determinants of OSA in the general population.44,45 
Ultimately, extra attention of sleep apnea occurrence and treatment should be paid to patients 
with CKD by both primary care providers and specialists. 
 Our study had several strengths including our enhanced focus on the burden of OSA in 
the U.S. veteran population by examining both point and period prevalence of the condition. 
We had a very large study population comprised of 6.2 million adult veterans with an extensive 
and frequently updated database including ICD and CPT codes to define OSA and several 
comorbidities. We also used statistical methods that take into account left censoring of 
veterans with different durations of follow-back and that adjust for potential confounders 
when comparing groups.  
One limitation of this study is that the identification of OSA diagnoses depends on 
claims data, which can lead to underdiagnosis or overdiagnosis of OSA and thus possible 
estimation bias, and it did not include OSA severity or detailed polysomnography findings. 
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Furthermore, residual confounding cannot be ruled out since we do not have information on 
certain risk factors for OSA such as smoking, alcohol consumption, socioeconomic status. 
Because we lacked BMI data on many veterans, we were not able to fully examine associations 
with obesity or adjust for this potential confounder. Generalization of our findings to all non-
veterans, especially women, may be limited. Moreover, our findings suggest that our use of Cox 
regression yielded reasonably valid results, at least for crude period-prevalence ratios. Although 
we could not check the validity of estimating adjusted period-prevalence ratios. In addition, the 
analysis of P and PP involved different mutually exclusive outcomes events. Unfortunately, we 
were not able to handle both types of events in the same analysis. Finally, we did not 
investigate OSA incidence in this study, which limits our ability to make causal inferences, but 
that topic will be addressed in Aim 3.  
In conclusion, the population burden of OSA, reflecting both point and period 
prevalence, is quite high in U.S. veterans, especially men with CKD. These findings, along with 
the associations of CKD risk factors with OSA, should be of potential importance to both 
researchers and providers of primary and specialty care. To further interpret and explain these 
findings, future work could assess trends in both prevalence and incidence of OSA. Future 
investigations of OSA should focus on identifying risk factors for this condition, assessing 
interactions of OSA with CKD, and identifying mechanisms that link CKD with OSA. Such efforts 
will contribute to reducing the burden of OSA and improving the quality of life in veterans and 
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Tables and figures 
 
Table 3.1: List of ICD-9, ICD-10, and CPT codes used to define obstructive sleep apnea, diabetes, 
hypertension, and CKD 
Type of coding Codes  
ICD-9 for obstructive sleep apnea 327.20, 327.22, 327.29, 327.8 
ICD-10 for obstructive sleep apnea G47.30, G47.33, G47.39, G47.8, G47.9, R06.00, 
R06.09, R06.3, R06.83, R06.89 
CPT for obstructive sleep apnea E0470 and E0601 
ICD-9 for diabetes 250, 35673, 36641, 36201,  36202 
ICD-10 for diabetes E08, E09, E10, E11, E13 
ICD-9 for hypertension 401, 402, 403, 404, 405 
ICD-10 for hypertension I10, I11, I12, I13, I15 
ICD-9 for CKD 016.0; 095.4; 189.0,189.9; 223.0; 236.91; 250.4; 
271.4; 274.1; 283.11; 403; 404; 440.1; 442.1; 
477.3; 572.4; 581-583; 585- 588; 591; 642.1; 
646.2; 753.12-753.19; 753.2; 794.4 
ICD-10 for CKD A18.11, A52.75, B52.0, C64.x, C68.9, D30.0x, 
D41.0x-D41.2x, D59.3, E08.2x, E09.2x, E10.2x, 
E10.65, E11.2x, E13.2x, E74.8, I12.xx, I13.0, 
I13.1x, I13.2, K76.7, M10.3x, M32.14, M32.15, 
N01.x-N08.x, N13.1, N13.1x-N13.39, N14.x,N15.0, 
N15.8, N15.9, N16, N17.x, N18.1-N18.5, N18.8, 
N18.9, N19, N25.xx, N26.1, N26.9, O10.4xx, 










Table 3.2: Summary statistics (mean [SD] or %) of the total study population of adult veterans at index 




(n = 6,220,481) 
No CKD 
(n = 5,301,945) 
CKD 
(n = 918,536) 
Age (mean [SD] in years) 60.9 (18.6) 59.4 (18.9) 70.8 (12.6) 
     18-44 (%) 22.2 25.0   3.5 
     45-64 (%) 28.6 29.4 23.3 
     ≥65 (%) 49.2 45.6 73.2 
Male (%) 88.0  86.7  96.2  
Race/ethnicity (%)    
     Hispanic   5.7   5.6   5.8 
     Non-Hispanic White 61.6 60.8 66.7 
     Non-Hispanic Black 14.7 14.1  18.5 
     Other non-Hispanic race 18.0 19.5   9.0 
Obesityb (%) 39.7 37.4 55.4 
Diabetes (%) 20.0  13.8  60.9 
Hypertension (%)  40.2  34.4 78.6  
aIndex time T for each veteran is the last VA visit in FY2018.  
bBMI ≥ 30. 
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Table 3.3: Computed point prevalence of OSA at index time Ta in the study population of adult 




(n = 6,220,481) 
No CKD 
(n = 5,301,945) 
CKD 
(n = 918,536) 
Numerator  1,033,231     806,454 228,777 
Denominator  6,220,481 5,301,945 918,536 
Point prevalence  16.6 15.2 24.9 





Table 3.4: Frequency distribution (number and %) of point-prevalent cases of OSA at time T and 
period-prevalent cases in 6-month intervals before T in the total study population, going back in time 
from the index time T in FY2018 to the start of FY2014 
 
Time/Interval Number (%) 








































Table 3.5: ∆-month PP (95% CI) (%) of OSA in the study population, by CKD status, using McFarland’s 
methoda, among all persons who did not have an OSA diagnosis at index time Tb 
∆ (months) Total CKD No CKD 
6 0.4 (0.4, 0.4) 0.4 (0.4, 0.4) 0.4 (0.4, 0.4) 
12 2.9 (2.9, 2.9) 3.5 (3.5, 3.6) 2.8 (2.8, 2.8) 
18 6.1 (6.1, 6.2) 8.2 (8.1, 8.2) 5.8 (5.8, 5.8) 
24 7.7 (7.7, 7.7) 9.9 (9.8, 10.0) 7.3 (7.3, 7.3) 
30 9.9 (9.8, 9.9) 12.9 (12.9, 13.0) 9.3 (9.3, 9.3) 
36 10.2 (10.2, 10.3) 13.3 (13.3, 13.3) 9.7 (9.7, 9.7) 
42 10.8 (10.8, 10.8) 14.1 (14.0, 14.2) 10.3 (10.2, 10.3) 
48 11.1 (11.0, 11.1) 14.4 (14.3, 14.4) 10.5 (10.5, 10.5) 
54 11.6 (11.5, 11.6) 15.0 (14.9, 15.1) 11.0 (10.9, 11.0) 
60 11.6 (11.6, 11.6) 15.0 (14.9, 15.1) 11.0 (11.0, 11.0) 
aMcFarland’s method takes into account left censoring during follow-back in the estimation of Δ PP of 
OSA. 







Table 3.6: ∆-month PP (%) of OSA, by CKD status, using the naive methoda, among all persons who did 
not have any OSA diagnosis at time Tb in the study population 
∆ (months) Total CKD No CKD 
6 0.4 (0.4, 0.4) 0.4 (0.4, 0.4) 0.4 (0.4, 0.4) 
12 2.7 (2.7, 2.7) 3.4 (3.4, 3.5) 2.6 (2.6, 2.6) 
18 5.6 (5.6, 5.7) 7.9 (7.8, 8.0) 5.3 (5.3, 5.3) 
24 7.0 (6.9, 7.0) 9.5 (9.4, 9.6) 6.6 (6.5, 6.6) 
30 8.8 (8.8, 8.8) 12.3 (12.2, 12.4) 8.2 (8.2, 8.3) 
36 9.1 (9.1, 9.1) 12.7 (12.6, 12.7) 8.5 (8.5, 8.6) 
42 9.6 (9.5, 9.6) 13.4 (13.3, 13.5) 8.9 (8.9, 9.0) 
48 9.7 (9.7, 9.7) 13.6 (14.5, 13.6) 9.1 (9.1, 9.1) 
54 10.0 (10.0, 10.0) 14.1 (14.0, 14.2) 9.4 (9.4, 9.4) 
60 10.0 (10.0, 10.0) 14.1 (14.0, 14.2) 9.4 (9.4, 9.4) 
aThe naïve method ignores left censoring during follow-back in the estimation of Δ PP. 




Table 3.7: Percentage of person-days of follow-back lost to left censoringa using McFarland’s method 
for estimating the Δ period prevalence (PP) of OSA in the restricted study population, by CKD status 
and 12-month interval prior to index time T 
12-month interval prior 








1-12 months 8.2 20.9 8.2 
13-24 months 42.2 56.2 41.1 
25-36 months 58.8 65.1 58.1 
37-48 months 77.1 77.3 77.1 
49-60 months 96.1 96.1 95.9 
1-60 months 76.3 87.7 74.5 
aThe difference between these two person-month sums reflects the amount of left censoring in 
McFarland’s method. The percentage of left-truncated follow-back was calculated by dividing that 
difference by the larger person-day sum using the naïve method.  
bMcFarland’s method takes into account left censoring during follow-back in the estimation of Δ PP of 
OSA. 




Table 3.8: Estimated associations (crude and adjusted point prevalence ratios [PR] and 95% CI) 
between selected covariates and OSA point prevalence, by CKD status, using modified Poisson 
regression, among all persons in the study population at index time T 
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Racea         
          NH 
White 
          (ref.)       
1 1  1 1  1 1 

























































































































 --- ---  --- --- 
aTo estimate the effects of age, sex, and race/ethnicity, adjustment is made for the two other 
demographic variables. 
bObesity (BMI ≥30 vs <30): adjusted for age, sex, and race/ethnicity.  
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cDiabetes: adjusted for age, sex, race/ethnicity, and obesity.  
dHypertension: adjusted for age, sex, race/ethnicity, obesity, and diabetes.  




Table 3.9: Estimated associations (crude and adjusted 60-month period prevalence ratios [PPR] and 
95% CI) between selected covariates and OSA period prevalence, by CKD status, using McFarland’s 
method with Cox regression, among all persons in the study population who did not have an OSA 
diagnosis at index time Ta 
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Raceb         
          NH White 
          (ref.)       
1 1  1 1  1 1 

























 (1.0, 1.1) 
0.99 
(0.96, 1.0) 




























































































 --- ---  --- --- 
aIndex time T is the last VA visit in FY2018.  
bTo estimate the effects of age, sex, and race/ethnicity, adjustment is made for the two other 
demographic variables.  
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cObesity (BMI ≥30 vs <30): adjusted for age, sex, and race/ethnicity.  
dDiabetes: adjusted for age, sex, race/ethnicity, and obesity.  
eHypertension: adjusted for age, sex, race/ethnicity, obesity, and diabetes.  




Table 3.10: Validity check of the Cox Regression procedure for estimating adjusted period prevalence 
ratios (PPR) using McFarland’s methoda with Cox regression, among all persons in the study 
population who did not have an OSA diagnosis at index time Tb 
Variable Category Crude PPR from 
Cox regression 
PP Ratio calculated 
by separate PP 
Age 18-44 1 11.91 1 
 45-64 1.19 13.97 1.17 
 ≥65 0.86 10.27 0.86 
Race White 1 11.49 1 
 Black 1.18 13.47 1.17 
 Hispanic 1.17 13.38 1.16 
 Other 0.72 8.47 0.74 
Sex Male 1.30 11.86 1.30 
 Female 1 9.26 1 
Obesity Yes 1.88 20.60 1.84 
 No 1 11.19 1 
Diabetes  Yes 1.52 15.44 1.48 
 No 1 10.40 1 
Hypertension Yes 1.22 12.71 1.21 
 No 1 10.53 1 
CKD Yes 1.40 15.02 1.37 
 No 1 10.99 1 
aMcFarland’s method takes into account left censoring during follow-back in the estimation of Δ PP of 
OSA.  
bIndex time T is the last VA visit in FY2018.cPeriod prevalence obtained from McFarland’s method for 








Figure 3.2: Δ period prevalence (PP in %) of OSA, by CKD status at index time T, using McFarland’s 
methoda, among all veterans in the study population who did not have an OSA diagnosis at index time 
Tb (Δ = 0) 
 
aMcFarland’s method takes into account left censoring during follow-back in the estimation of Δ PP of 
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91 
 
Figure 3.3: Δ period prevalence (PP in %) of OSA, by CKD status at index time T, using the naive 
methoda, among all veterans who did not have an OSA diagnosis at index time Tb (Δ = 0) 
 
aThe estimation of Δ PP, using the naïve method, ignores left censoring during follow-back (i.e., it 
assumes detection of OSA diagnoses during follow-back extends to the start of FY2014). bIndex time T is 
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Figure 3.4: Δ period prevalence (PP in %) of OSA, by CKD status at index time T, comparing 
McFarland’s methoda (red lines) with the naïve methodb (blue lines), by CKD status (solid vs. dashed 
lines), among all veterans in the study population who did not have an OSA diagnosis at index time Tc 
(Δ = 0) 
 
 
aMcFarland’s method takes into account left censoring during follow-back in the estimation of Δ PP of 
OSA. bThe estimation of Δ PP, using the naïve method, ignores left censoring during follow-back (i.e., it 
assumes detection of OSA diagnoses during follow-back extends to the start of FY2014).cIndex time T is 
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Table 3A. McFarland’s method for estimating period prevalence 
We modify McFarland’s method slightly and extend his method to estimate ratio measures of 
associations.  
Let 





where U(i,t) is an indicator (coded 1,0) of whether that member of the study population was a 
user of VA facilities (not left truncated) at time t; C(i,t) is an indicator (1,0) of whether that VA 
user was known to have OSA at time t.  Thus, R(t) is the number of VA users who are not known 
to have OSA in at time t, i.e., the “risk set,” who are eligible to be observed as OSA cases before 
time t 
Let 




for t > 1. Thus, D(t) is the number of persons in the risk set at time t and are known to have OSA 
at time t−1; D(1) is defined as 0.  
PP(t) is estimated using the product-limit (Kaplan-Meier) method of “risk” estimation,  







The variance of this PP estimate is 
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Source: McFarland BH. Comparing period prevalences with application to drug utilization. J Clin 





Table 3B. Estimating the proportion of follow-back due to left censoring 
In the naïve method, we assume implicitly that all persons in the restricted study population 
who were not found to have an OSA diagnosis during the 5-year study period (size N0) were 
followed back from Ti to the start of FY2014 (i.e., Ti − t0 ≤ 60 months). All persons who were first 
found to have an OSA diagnosis (size N1) at time ti during the study period were followed-back 
for (Ti − ti) months. Therefore, the total number of person-months (PM) accrued by the 
restricted study population using the naïve method would be: 






where the first summation is across all noncases of OSA (i = 1,…,N0), and the second summation 
is across all diagnosed cases of OSA (i = 1,…,N1). 
 
In McFarland’s method, we count person-months of follow-back from Ti to time ti when the 
person is either first found to have an OSA diagnosis or left-truncated as a noncase on or before 
reaching t0. Therefore, the total number of person-months (PM) accrued by the study 
population using McFarland’s method is: 




where summation is across all persons in the restricted study population (i = 1,…,N). 
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Thus, the difference between these two person-month sums reflects the amount of censoring 
in McFarland’s method. We can express the proportion of follow-back that is censored (%PM) 
by dividing that difference by the larger naïve PM, i.e., 





Source: McFarland BH. Comparing period prevalences with application to drug utilization. J Clin 







Aim 3: Explaining Racial Disparity on Obstructive Sleep Apnea Mediated by Chronic Kidney 
Disease 
Abstract   
 
Background: To better understand the effect of race/ethnicity on the incidence of obstructive 
sleep apnea (OSA), we conducted a large retrospective cohort study of U.S. veterans to test the 
hypothesis that chronic kidney disease (CKD) is a mediator in the causal pathway linking 
race/ethnicity with OSA. 
Methods: Using data from 3.5 million veterans for FY2016-2018, we estimated direct, indirect, 
and total effects of race/ethnicity on OSA, and percentages of the total effect mediated by CKD, 
adjusting for age, sex and other CKD risk factors. Non-Hispanic Blacks, Hispanics, and other non-
Hispanic races were compared with non-Hispanic Whites, using 4 methods of mediation 
analysis: the informal difference method (similar to confounder adjustment, likely to be 
biased); 4-way decomposition of the race/ethnicity effects (assessing mediation and interaction 
by CKD); flexible mediation analysis (assessing mediation by CKD and its 3 main risk factors—




Results: Compared with Whites, Blacks and Hispanics had moderately higher incidence rates of 
OSA and other races had lower rates. The percentages of the total race/ethnicity effects 
mediated by CKD were small and similar using all 4 mediation methods; relative to Whites, it 
ranged from 5.8% to 7.4% for Blacks, 2.3% to 2.8% for Hispanics, and −0.12% to 0.51% for other 
races. Most of the total effects (>90%) were due to direct effects. However, when CKD and its 3 
risk factors were treated collectively as mediators in flexible mediation analysis, the percentage 
mediated relative to Whites increased from 5.8% to 30.3% for Blacks, from 2.6% to 2.9% for 
Hispanics, and from 0.2% to 16.4% for other races. In the 4-way decomposition of the 
race/ethnicity effects, the percentages of the total effects due to race/ethnic-CKD interactions 
was small (<3% in all race/ethnicity comparisons).   
Conclusion: Most of the racial/ethnic disparity in OSA incidence was not explained by 
mediation or interaction with CKD, yet a modest percentage of the Black/White disparity was 
attributable to the combination of CKD and its 3 main risk factors. All 4 mediation methods 
yielded consistent findings, including the simpler difference method, but such similarities would 
not necessarily apply to other racial/ethnic disparities in veterans or other populations. As new 
and refined methods of mediation analysis are developed to handle the many types of data and 
potential sources of bias encountered in these analyses, they should prove to be valuable in 





Obstructive sleep apnea (OSA), characterized by transient, repetitive partial or complete 
occlusion of the upper airway, is a growing public-health problem in the United States.1 Greater 
prevalence and severity of OSA have been observed in Blacks than in White.2,3 Wallace et al.4 
focused on race/ethnicity as a modifier of the effect of the adherence of primary treatment 
(continuous positive airway pressure, CPAP) on functional sleep outcomes, such as difficulty of 
concentrating because of sleepiness. CPAP adherence was positively associated with social and 
intimacy functional outcomes among Blacks, while this association was not seen in Whites. 
Billings et al.5 showed that sleep duration partially explained the association between race and 
CPAP adherence in the general population. Sleep disturbances include longer sleep latency (the 
length of time that it takes to accomplish the transition from full wakefulness to sleep), poor 
sleep quality, easily awaken and less deep sleep, and more frequent and longer naps resulting 
in reduced health-related quality of life for Blacks.6  
In addition to the higher prevalence of OSA compared with Whites, Blacks also have a 
higher prevalence of CKD, a higher risk of progression to ESRD, an earlier start of dialysis, and a 
higher mortality rate after age 30.7 Genetic predisposition (apoliprotein-L1) in Blacks 
purportedly accounts for 70% of the attributable risk of CKD.8 In addition, based on the 
evidence that even after care is standardized, CKD outcomes remain differential for minorities, 
non-health care system factors may play a crucial role for CKD.9 Study results have shown that 
declining kidney function increases the prevalence of sleep apnea and nocturnal hypoxia.10,11 In 
addition, CKD may lead to OSA through a variety of mechanisms, including alterations in 
chemoreflex responsiveness, pharyngeal narrowing due to fluid overload, accumulation of 
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uremic toxins, OSA-related changes in sympathetic tone, neurohumeral output, and 
tubulointerstitial hypoxia.12,13 Thus, it is possible that the higher prevalence and incidence of 
OSA in Blacks can be explained in part by the elevated prevalence of CKD in this group or by the 
interaction between race and CKD.  
This study’s goal was to assess whether and to what extent the excess incidence of OSA 
among race/ethnicity (Hispanics; Blacks; and other NH races) relative to Whites in US veterans 
could be explained by the occurrence of CKD acting as a mediator of the race “effect.” 
Mediation implies that race affects the risk of CKD, which affects the risk of OSA; i.e., there is an 
indirect effect of race on OSA, mediated in part by CKD. In addition, there may be a direct effect 
of race on CKD, which is mediated by other factors. Our hypothesis was that CKD helps to 
explain race/ethnicity effects, especially Blacks vs Whites, on OSA incidence by mediating the 
race/ethnicity effects on OSA; i.e., race/ethnicity-->CKD-->OSA . To achieve this objective, we 
used four types of mediation analysis: the difference method;14 4-way decomposition,15 flexible 
mediation analysis16 and dynamic path analysis.17 The latter three methods have different 
statistical advantages and limitations for dealing with our data so they complement each other; 
the first method, which is simpler and has been used informally for many years in 
epidemiology, is used for comparison.    
Methods 
Source population and study design 
This study was deemed “non-regulated” by the Institutional Review Board at the 
University of Michigan, as veterans health administration (VHA) system provides de-identified 
data as part of the Centers for Disease Control and Prevention’s CKD Surveillance System 
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Contract with the University of Michigan. The VHA system is the nation's largest integrated 
health care system, which contains an abundance of health information of veterans followed 
longitudinally.18 Veterans Health Information Systems and Technology Architecture (VistA) 
includes the VA’s electronic health records. From VistA, National Data Systems makes the 
extracts available and turns them into Medical SAS datasets (MedSAS). Inpatient, Outpatient, 
Lab, and Pharmacy electronic medical records were accessed from MedSAS Dataset and 
Department of VA Corporate Data Warehouse files using the U.S. Veterans Administration 
Informatics and Computing Infrastructure (VINCI) system.19  
The study is a retrospective cohort study of eligible U.S. veterans. Patients were 
included in the study if they sought care in the VA medical system with at least one visit in each 
of the three years (FY2014, FY2015, and FY2016), had information on date of birth, and were at 
least 18 year-old in FY2016, not having any OSA diagnosis from FY2014-FY2016. Theses selected 
participants were followed from the last visit in FY2016 up to the first diagnosis in FY 2017-
FY2018 (incident OSA cases) or to the last visit in FY2017-2018 (noncases). The final study 
population contained 3.5 million participants.  
Study variables 
Outcome: incident OSA 
De-identified inpatients and outpatients with OSA diagnoses were extracted from 
MedSAS and CDW databases. OSA was based on multiple ICD-9-CM or ICD-10-CM codes related 
to OSA and CPT code for continuous positive airway pressure (CPAP) treatment (see Table 1 for 
codes). Incident OSA was defined as not having any OSA diagnosis from FY2014-FY2016, but 
102 
 
having a new OSA diagnosis after the last visit in FY2016 to the end of FY2018. Binary incident 
OSA status (yes vs. no) was used as the outcome measure in three of the mediation analyses: 
the difference method, four-way decomposition, and flexible mediation. Time-to-incident OSA 
was used in dynamic path mediation analysis. Participants were followed from the last visit in 
FY2016 up (baseline) to the first diagnosis in FY 2017-FY2018 (incident OSA cases) or to the last 
visit in FY2017-2018 (noncases). In dynamic path analysis, follow-up time was divided into 
follow-up intervals: days 1-250, 251-500, 501-750, and >750. 
Binary mediator: prevalent and incident CKD 
De-identified inpatients and outpatients with CKD diagnoses were extracted from 
MedSAS and CDW databases. CKD status was based on the presence of at least one of three 
criteria: having a diagnosis of ICD-9 or ICD-10 CKD (see Table 1 for codes); an eGFR <60 
ml/min/1.73 m2, using the CKD-EPI formula; and the presence of albuminuria (urine albumin-to-
creatinine ratio [UACR] ≥30 mg/g).20 These three criteria were applied to identify CKD 
prevalence at baseline and CKD incidence during follow-up. In dynamic path analysis, the 3 
criteria were used to identify CKD incidence during follow-up (prior to becoming an OSA 
incident case), i.e., treating CKD as time-dependent.  
Covariates: age, sex, hypertension, diabetes, obesity/BMI 
Data for measuring covariates at baseline were retrieved from MedSAS and CDW 
databases and included date of birth, date of last VA visit in FY2016, sex, height and weight 
(average of last two values), diabetes status and hypertension status (see codes in Table 1). 
Obesity was defined as a body mass index (BMI) ≥30 kg/m2. In dynamic path mediation analysis, 
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BMI was treated as a time-dependent confounder. Covariates believed to be confounders were 
adjusted for in the models based on the DAG in Figure 1. 
Exposure: race/ethnicity 
Race and ethnicity were classified together into 4 categories: Whites non-Hispanic (67.3% of 
the study population) treated as the reference group; Black non-Hispanic (16.1%); Hispanics 
(any race; 5.5%); and other non-Hispanic races (11.1%, including American Indian/Alaska 
Native, Asian, Native Hawaiian/Pacific Islander, and other). Hereafter, these groups will be 
labeled Whites, Blacks, Hispanics, and other races. 
Statistical analysis 
Descriptive statistics are presented as percentages for categorical variables and as 
means and standard deviations (SD) for continuous variables. The crude incidence rate of OSA 
for each race/ethnicity and for the total study population was calculated as the number of new 
OSA diagnoses, divided by total person-days of follow-up;  rates are expressed per 1000/year. 
Cox regression was used to estimate hazard ratios (HR and 95% CIs) for crude and 
adjusted associations between the covariates of interest and OSA incidence rate, by type of 
model adjustment. In one adjusted model, we only adjusted for age, sex, and race/ethnicity 
(where needed). To adjust for potential confounders in the analysis, but not mediators, we 
used the causal diagram (directed acyclic graph) in Figure 1 to guide the analysis of the 
covariates of interest including CKD in the other adjusted model. 
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The difference method, 4-way decomposition, flexible mediation analysis, and dynamic 
path mediation analysis were used in the study because of the need for taking exposure-
mediator interaction into account when estimating the direct and indirect effects of the 
exposure on an outcome (not done in the difference method); the advantage of assessing the 
amount of that interaction in a mediation analysis (specifically in the 4-way decomposition); the 
4th no-confounding assumption, which is particularly relevant in this study because the 
exposure (race/ethnicity) affects many factors of interest aside from CKD, including risk factors 
for CKD;  the advantage of analyzing multiple mediators to get around that previous issue (with 
flexible mediation analysis, medflex); and taking censoring into account when outcome events 
are observed over time (with dynamic path analysis); apparently low estimation precision with 
dynamic path analysis (wide CIs), presumably due to repeated measures of time-varying 
mediators and confounders and to use of bootstrapping for obtaining confidence limits. Details 
of the 4 different mediation analysis methods are provided in the Method section. 
Difference method 
The “difference method” of mediation analysis is the simple approach used informally 
by epidemiologists for many years, similar to adjustment for confounders.14 Two regression 
models are fit to the data: one includes as predictors the exposure of interest, the hypothesized 
mediator(s), and potential confounders; the other model is similar but excludes the 
mediator(s). The estimated exposure effect in the second model is the total effect. The 
estimated exposure effect in the first model is the direct effect (not mediated by the 
predictor(s) excluded from the second model). The difference between the estimated exposure 
effect in those two models is assumed to be the indirect (mediated) effect of the exposure.  
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Age, sex, diabetes status, hypertension status, and BMI (continuous) were treated as 
baseline confounders. CKD was treated as fixed baseline mediator. Binary OSA—a new 
diagnosis any time during follow-up--was treated as the outcome. Two Cox regression models 
were run for race/ethnicity comparison.  One Cox regression adjusted for only age and sex or all 
baseline confounders (age, sex, diabetes, hypertension, and BMI). The other one adjusted for 
only age and sex or all baseline confounders in addition to the mediator (CKD). The hazard ratio 
(HR; 95% CI) of the direct effect is obtained from the regression coefficient for the 
race/ethnicity predictor in the Cox model with CKD. The HR for the indirect effect is the antilog 
of the difference between the log HRs for the total effect and the direct effect on the log scale. 
The total effect (HR; 95% CI) is obtained from the regression coefficient for the race/ethnicity 
predictor in the Cox model without CKD. The proportion mediated is the log HR for the indirect 
effect divided by the log HR for the total effect. 
A limitation of this approach is that it gives biased results for direct and indirect effects 
when there is an interaction between the exposure and mediator; that disadvantage does not 
apply to the other three mediation methods.  
Four-way decomposition method 
A 4-way decomposition of the exposure effect, as developed by VanderWeele,21 not 
only takes exposure-mediator interactions into account, but it decomposes the total effect into 
4 components due to: neither mediation nor interaction (controlled direct effect); interaction 
only (“reference interaction”); both interaction and mediation (“mediated interaction”); and 
mediation only (pure indirect effect). The sum of the first two components is called the “pure 
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direct effect,” and the sum of the latter two components is called the “total indirect effect.” 
The total indirect effect divided by the total effect—the sum of all 4 components—is the (total) 
proportion mediated. 
The first logistic model was fitted on incident OSA by race variable (race/ethnicity vs 
White NH), CKD and hypertension, diabetes, BMI, sex, and age. Then the other logistic model 
was fitted with CKD as the outcome by race variable, hypertension, diabetes, BMI, sex, and age. 
Covariates adjusted for in the models as potential baseline confounders were age, sex, BMI 
(continuous), diabetes, hypertension. Binary exposure and binary outcome were used for this 
analysis. Each race/ethnicity versus Whites was included in a separate model, excluding person 
in the other two groups. Separate models are required for each exposure comparison because 
the SAS procedure does not accommodate multiple categories of the exposure. The Causalmed 
procedure in SAS 9.4 was used to perform this mediation analysis.  
One limitation of this approach is violation of no-confounding assumption that is unique 
to mediation analysis: The exposure should not affect a confounder of the mediator effect on 
the outcome, which implies that the confounder is also another mediator.15 This assumption 
could easily be violated in this study because race/ethnicity affects many conditions including 
the comorbidities modeled as potential confounders in these analyses. Another limitation is 
that prediction of the OSA incidence does not take censoring into account. 
Flexible mediation analysis  
Flexible mediation analysis, developed by Steen and colleagures,16,22 involves fitting a 
“natural effect” model to the outcome, conditional on nested counterfactuals, i.e., the 
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expected value of the outcome, given the exposure and what the mediator would be if 
everyone’s exposure were set to the reference level (Whites in this study). Unobserved 
counterfactuals are imputed using any appropriate model of the outcome mean; both natural 
direct and indirect effects are obtained from the coefficients of the model. The flexibility of this 
approach allows the user to avoid violation of the no-confounding assumption described above 
by incorporating multiple mediators jointly. Thus, this application of flexible mediation analysis 
can be used to estimate the natural indirect effect of all measured mediators (provided there 
are no other unmeasured mediators or confounders). 
We applied flexible mediation analysis in three ways: treating CKD as the only mediator; 
treating CKD and its 3 risk factors (hypertension, diabetes, BMI) jointly as mediators; and 
treating the 3 risk factors (without CKD) as the mediators. The race/ethnicity effects were 
adjusted for age, sex, hypertension, diabetes, and BMI when CKD was treated as the only fixed 
baseline mediator. The race/ethnicity effects were adjusted for age, sex when treating CKD and 
its 3 risk factors jointly as mediators and treating the 3 risk factors as the mediators. Three 
indicator predictors (race/ethnicity) and binary outcome (OSA) were used for this analysis. All 
the race/ethnicity (Blacks, Hispanics, other NH races) versus Whites were included in the same 
model. The medflex package in R was used to perform this mediation analysis.22 
  First, we fitted a mean model for the outcome by CKD, race/ethnicity, and covariates 
(age, sex, BMI, hypertension, diabetes) in a logistic regression model. Second, we expanded the 
data so that the exposure could take on values different from the observed exposure 
(counterfactual exposure values). Next, we imputed the nested counterfactual outcomes by 
fitted values based on the imputation model. Finally, after expanding and imputing the data, we 
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fitted the natural effect model on the imputed data to get the estimates. A logistic model was 
fitted on incident OSA by race variable (race/ethnicity vs White) and the covariates. Robust 
stand errors based on sandwich estimator23 were requested from the model. Adjusted odds 
ratio (OR; 95% CI) for the natural direct effect (NDE) and natural indirect effect (NIE) were 
obtained from the models. Total effect was calculated as the product of NDE and NIE. The 95% 
CI for the TE was not computed because it is computationally complex and not needed for 
interpretation of the main findings. The percentage mediated on the risk difference scale is 
NDE(NIE−1)/(NDE×NIE−1), where NDE and NIE are the odds ratios (OR) corresponding to those 
effects, assuming OSA incidence is a rare outcome event. 
A limitation that this approach shared with the previous mediation method is that 
prediction of OSA incidence does not take censoring into account; the outcome is binary (OSA 
case/noncase). Another limitation shared with the other methods is that the mediator is a fixed 
baseline measure; therefore, the magnitude of its associations with the exposure and outcome 
may depend on mediator changes that occurred years before baseline.   
Dynamic path mediation analysis  
The mediation method proposed by Vansteelandt et al.17 is a generalization of dynamic 
path analysis that involves a time-to-event outcome and treats the mediator and time-varying 
confounders as time-dependent during follow-up. This approach assumes an additive hazard 
model for the outcome and a linear regression model for the mediator. The method allows 
time-dependent confounders to be influenced by the exposure at baseline (time t=0), i.e., 
avoiding the no-confounding assumption described previously. Pure direct and indirect effects 
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and the total effect of the exposure are expressed as differences or ratios of counterfactually 
defined survival probabilities (free of OSA) at time t. The proportion mediated is estimated as 
the ratio of the pure indirect effect to the total effect, each expressed as a difference in survival 
probabilities. 
CKD was treated as the time-dependent mediator, and BMI was treated as a time-
dependent cofounder. Age, sex, diabetes, and hypertension were treated as fixed confounders 
at baseline. Binary exposure race/ethnicity and time-to-incident OSA (outcome) were used for 
this analysis. A separate mediation analysis was done for each comparison of a race/ethnicity 
with Whites, excluding persons from the other two racial/ethnic groups The SAS macros 
provided by Vansteelandt et al.17 were used to perform this mediation analysis.  
 Cox regression models and quasi-binomial regression models (logit link instead of probit 
link) were used during the procedure to obtain estimated probabilities S0,0(t), S1,0(t), and S1,1(t) 
for each interval. Total effect was expressed as S1,1(t)- S0,0(t) whereas direct effect was 
expressed as S1,0(t)- S0,0(t). Percentage mediated was expressed as (total effect-direct 
effect)/total effect. 
A limitation of this method is low precision for estimating parameters (i.e., wide 
confidence intervals), which is due to the use of repeated measures of time-varying mediators 
and confounders (CKD and BMI in this study) and to the use of bootstrapping for obtaining 
confidence limits; moreover, the SAS macro takes a long time to run and models may not 
converge.  





 Table 2 shows summary statistics (mean and standard deviation [SD] or percentage) for 
selected measures, by race/ethnicity, in the total study population of 3,529,213 participants 
(last visit in FY2016). The mean age was 64 years, 91% were male, 67% were White, 16% were 
Black, 6% were Hispanic, and 11% were other races. Compared to Whites, Blacks were more 
likely to be younger, female, obese, have diabetes, hypertension, CKD, shorter follow-up time, 
higher OSA incidence rate. Compared to Whites, Hispanic were more likely to be younger, 
female, obese, have diabetes, CKD, shorter follow-up time, higher OSA incidence rate. Other 
races were more likely to be younger, female, less obese, have longer follow-up time, lower 
OSA incidence rate comparing to Whites. 
 Table 3 shows crude and adjusted hazard ratios (HR; 95% CI) for the associations 
between the covariates of interest and OSA incidence rate, by type of model adjustment, in the 
total study population. Using Cox regression, the hazard ratio (HR; 95% CI) for each covariate 
was adjusted for race/ethnicity, sex, and age (middle column) in addition to other confounders, 
but not mediators, as implied by the DAG in Figure 1 (right column). In the fully adjusted model, 
the HR of OSA for each racial/ethnic group, compared with Whites, was 1.13 (1.12, 1.14) for 
Blacks, 1.12 (1.11, 1.13) for Hispanics, and 0.82 (0.81, 0.83) for other races. The adjusted HRs 
for CKD, diabetes, and hypertension (all binary) were about the same (1.21 to 1.26), but the 
association with OSA was stronger for obesity (adjusted HR = 2.01; 2.00, 2.03).  
 The informal difference method was used to generate the findings in Table 4, which 
shows adjusted HR and 95% CI for the direct effect, indirect effect, and total effect of each 
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race/ethnicity (vs. Whites) on OSA incidence, and the percentage mediated by CKD. Compared 
with Whites, the OSA incidence rate was higher for Blacks (HR = 1.091; 1.082-1.101) and 
Hispanics (HR = 1.117; 1.103-1.131), but lower for other races (HR = 0.912; 0.902-0.922). Blacks 
had the largest % mediated by CKD (6.6%), Hispanics had the second largest % mediated by CKD 
(2.8%) and other races had the smallest % mediated by CKD (-0.12%). In the model without 
adjustment of potential mediators (BMI, diabetes, hypertension), all the effects (total, direct, 
and indirect) increased comparing with the model with adjustment of potential mediators. The 
percentage mediated relative to Whites increased from 6.6% to 20.1% for Blacks, from 2.8% to 
14.3% for Hispanics, and decreased from -0.12% to -1.6% for other races. 
 The 4-way decomposition method was used to generate results for Table 5. The 
percentage mediated for pairs of component effects can be summed to reflect the pure direct 
effect (controlled direct + reference interaction), the total indirect effect (mediated interaction 
+ pure indirect), and total interaction (reference interaction + mediated interaction). Table 5 
presents the adjusted odds ratios (OR; 95% CI) for the 4 component effects of each 
race/ethnicity (vs. Whites) on OSA incidence, due to mediation and/or interaction with CKD, 
using logistic regression. The OR for the total effect of Blacks versus Whites race was 1.11 (1.10-
1.11); the OR for the total effect of Hispanics versus Whites was 1.13 (1.11-1.15); and OR for 
other races versus Whites was 0.904 (0.894- 0.915).  
For Blacks versus Whites, the pure indirect effect accounted for 6.8% (95% CI: 6.0, 7.5) 
of the total effect; the component due to the mediated interaction was 0.68% (0.64, 0.71); the 
component due to the reference interaction is 2.2% (2.1, 2.3); and the component due to the 
controlled direct effect (if CKD were fixed to 0) was 90.4% (89.6, 91.2). Of these four 
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components, the controlled direct effect was the most substantial. The overall proportion 
mediated was 7.4%. The overall proportion attributable to interaction was even smaller, 2.9%.  
For Hispanics versus Whites, the component due to the pure indirect effect accounted 
for 2.1% (95% CI: 1.7, 2.4) of the total effect; the component due to the mediated interaction 
was 0.26% (0.23, 0.30); the component due to the reference interaction is 2.4% (2.2, 2.5); and 
the component due to the controlled direct effect (if CKD were fixed to 0) was 95.3% (95.9, 
95.8). Of these four components, the controlled direct effect was again the most substantial. 
The overall proportion mediated was 2.3%. The overall proportion attributable to interaction 
was 2.7%.  
For other NH races versus Whites, the component due to the pure indirect effect 
accounted for 0.57% (95% CI: 0.31, 0.83) of the total effect; the component due to the 
mediated interaction was -0.05% (-0.08, -0.03); the component due to the reference interaction 
is 2.4% (2.3, 2.6); and the component due to the controlled direct effect (if CKD were fixed to 0) 
was 97.1% (96.8, 97.3). Of these four components, the controlled direct effect was the most 
substantial. The overall proportion mediated was quite small, 0.51%. The overall proportion 
attributable to interaction was 2.4%. Neither interaction nor mediation components of CKD 
contributed significantly to the overall effect of race/ethnicity on the risk of incident OSA. 
 Flexible mediation analysis was used to generate results for Table 6, which shows three 
sets of analysis: CKD is treated as the only mediator in the top panel;  CKD plus its three risk 
factors (diabetes, hypertension, and BMI) are treated jointly as mediators in the middle panel, 
and the three risk factors (without CKD) are treated as mediators in the bottom panel. Adjusted 
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odds ratios (OR; 95% CI) reflect the natural direct effect (NDE), the natural indirect effect (NIE), 
and the total effect (TE) of each race/ethnicity comparison on OSA incidence; also shown in the 
table are the percentages mediated. When treating CKD as the only mediator, the ORs of Blacks 
for the NDE was 1.10 (95% CI: 1.09, 1.11). The OR for the NIE is 1.01 (95% CI: 1.01, 1.01). 5.8 
percent of the total effect (OR=1.11) of Blacks vs Whites on incident OSA is mediated by CKD. 
For Hispanics, the OR for the NDE was 1.13 (1.11-1.14).  The OR for the NIE was 1.00 (1.00-
1.01). 2.6 percent of the total effect (OR=1.13) of Hispanic vs White on incident OSA was 
mediated by CKD. For other races, the OR for the NDE was 0.83 (95% CI: 0.82, 0.84). The OR for 
the NIE is 1.00 (1.00-1.00). Only 0.2% of the total other races vs White effect on OSA incidence 
was mediated by CKD. 
 When treating CKD and its three risk factors as mediators (middle panel of Table 6), the 
NIE for Blacks increased from 1.01 (1.01, 1.01) to 1.04 (1.04, 1.04). This leads to an increase in 
the percentage mediated from 5.8% to 30.3%. For other NH races, the OR for the NIE decreased 
from 1.00 (1.00, 1.00) to 0.96 (0.96, 0.96). The percentage mediated increased from 0.2% to 
16.4%. Results for Hispanics vs Whites remained similar when treating all 4 comorbidies as 
mediators. 
When treating three risk factors as mediators (lower panel of Table 6), the results 
remained similar to results from the middle panel. The percentage mediated decreased slightly 




Table 7 shows the results from dynamic path mediation analysis. It shows the estimated 
pure direct effect (PDE), pure indirect effect (PIE), and TE of each race/ethnicity (vs Whites) on 
OSA incidence, and the percentage mediated by CKD, stratified by follow-up interval during 
follow-up. For Blacks vs Whites, the percentage mediated decreased over time (from 6.1% for 
days 250-500, to 4.9% for days 501-750, to 2.6% for days 750+). For Hispanic versus Whites, the 
percentage mediated decreased from 2.9% for days 250-500, to 2.1% for days 501-750 day, to 
0.97% for days 750+). The magnitude of the total effect would have been slightly greater in the 
absence of CKD mediation for other NH races versus Whites; the percentage mediated is very 
small but negative after day 250. 
Discussion 
Our analysis of data from 3.5 million veterans for FY2016-2018, using four mediation 
analysis methods shows that most of the racial/ethnic disparity in OSA incidence was not 
explained by mediation or interaction with CKD. The percentage of mediated by CKD of the 
total effect from the largest to the smallest was Black, Hispanic, and other races. Results 
showed similar mediated effects of CKD across different meditation analysis methods. 
However, when CKD, hypertension, diabetes and BMI were treated jointly as mediators in 
flexible mediation analysis, the percentage of mediated for Blacks and other NH races increased 
appreciably. The percentage mediated by CKD decreased after day 500 using dynamic path 
mediation analysis.  
There are pros and cons of the four mediation methods we applied in our study (Table 
8). The difference method is easy to implement since there is no requirement of any package or 
macro. However, it relies on the assumptions of no interaction between race/ethnicity and CKD 
115 
 
and no measured or unmeasured confounders of the CKD-OSA effect that are influenced by 
race/ethnicity.  
The 4-way decomposition approach is also easy to implement because there is a built-in 
procedure in the latest SAS 9.4 version. In addition, the total effect of race/ethnicity on OSA can 
be decomposed into four components. These four components corresponded to the portion of 
the effect that is due to neither mediation nor interaction, to interaction only, to both 
mediation and interaction, and to mediation only.15 However, this SAS procedure cannot be 
applied to a multi-category exposure such as race/ethnicity. Therefore, we did a separate 
analysis with each racial/ethnic comparison, excluding all persons from the other two 
racial/ethnic groups. Furthermore, the estimates can be biased if the data violate the 4th 
assumption (no measured or unmeasured confounders of the CKD and OSA effect that are 
influenced by race/ethnicity).  
The flexible mediation analysis can be applied to data with multiple mediators. The 
standard errors of the estimates can be obtained by either bootstrapping or robust standard 
error based on sandwich estimator. Path-specific indirect effect cannot be estimated with 
current version of medflex package.  
Finally, dynamic path mediation analysis was designed for data with time-to-event 
outcome, time-varying mediators, and time-varying confounders to capture the full complexity 
of the mediators. Nevertheless, this approach takes a lot of time and memory to run in SAS, can 
only be used for data with binary exposure, only generates confidence intervals through 
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bootstrapping leading to a loss of precision, and might not produce valid results if the model 
does not converge when the confounders or mediators are binary.  
Although similar percentages of mediated by CKD were observed across different 
mediation methods, it should be noted that valid estimates can only be identified from the data 
on average for a population under no-confounding assumptions.21 In particular, the 
identification of effects relies on four strong assumptions of no unmeasured confounders of: 1) 
the exposure-mediator effect, 2) the exposure-outcome effect, or 3) the mediator-outcome 
effect; and 4) no measured or unmeasured confounders of the mediator-outcome effect that 
are influenced by exposure. In our study, diabetes, hypertension, and BMI could not only be the 
confounders between CKD and OSA but also be affected by race/ethnicity. Such additional 
mediation could bias the results. However, flexible mediation analysis and dynamic path 
mediation analysis are able to deal with measured mediator-outcome confounders influence by 
the exposure. The flexible mediation analysis,16 avoid the violation of this assumption by 
treating all measured mediators jointly as a group. However, a sequential approach enabling 
effect decomposition of the total indirect effect into multiple path-specific effects embedded in 
the natural effect model framework is only available in an upcoming version the medflex 
package.22 On the other hand, dynamic path analysis does properly control for measured 
mediator-outcome confounders influenced by the exposure if they are treated as time-
dependent covariates during follow-up, which was done in this study with BMI.17 This strategy, 
however, was not possible with diabetes and hypertension, which could be treated only as fixed 
baseline covariates. Therefore, time-dependent mediators and confounders are allowed to 
capture the mediated and direct effect throughout the follow-up. 
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The association between race/ethnicity and OSA, measured as a ratio, is stronger with 
prevalence data (see Chapter 3) than with incidence data. The adjusted HR from the model with 
race/ethnicity as the exposure and prevalent OSA as the outcome for other NH races was 0.72 
(0.72, 0.73) for other NH races. In contrast, the adjusted HR from the model with race/ethnicity 
as the exposure and incident OSA as the outcome for other NH races was 0.82 (0.81, 0.83). 
Because prevalence is based on both incidence and the course of disease (from recovery and 
death), relatively high prevalence of a disease in a population could reflect higher incidence 
and/or prolonged survival without recovery.24 A systematic review by Saha et al.25 summarized 
the sources of racial disparities contributing to differential prevalence in chronic diseases and 
preventive and ambulatory care in the VHA system. These sources of racial disparity could 
result from degree of familiarity with and knowledge about medical interventions, less trust 
and more skepticism in minority veterans, inadequate racially and culturally concordant 
healthcare environment, lower participation in care in non-white veterans, differential 
clinicians' diagnostic and therapeutic decision making, limited social support and external 
resources of illness management and decision making in non-white veterans, fewer available 
services and lower quality care.25 Therefore, the stronger ratio-measure association in other NH 
races vs. White with prevalence data comparing to with incidence data more likely ascribes to 
different duration of illness (prolonged survival without cure) than lower incidence of OSA in 
other NH races. 
CKD partially mediated the effect of race/ethnicity on incident OSA, especially for Blacks 
vs. Whites in our study. OSA is an important comorbidity in patients with CKD or end-stage 
renal disease (ESRD). A few studies have shown the racial disparity in CKD occurrence and 
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reported the occurrence of OSA in persons with CKD. The prevalence of nocturnal hypoxia was 
three times higher in patients with eGFR<60 mL/min/1.73 m2 than in patients with eGFR>60 
mL/min/1.73 m2 (48% vs 16%). In addition, Nicholl et al.10 demonstrated that the prevalence of 
sleep apnea increased as eGFR declined (41% for CKD and 27% for eGFR>60 mL/min/1.73 m2) 
among patients from outpatient nephrology clinics and hemodialysis units. Sakaguchi et al.11 
found that a 10 ml/min per 1.73 m2 decrease in eGFR was associated with a 42% increased odds 
of OSA after adjusted for age, BMI, and diabetes among non-dialysis hospitalized CKD patients. 
Elias et al.26 showed that nocturnal rostral fluid shift is associated with the severity of OSA in 
ESRD patients on conventional hemodialysis. 28% of stages 2-4 non-dialysis CKD patients were 
at high risk of OSA (2 or more categories where the score is positive) using the Berlin 
questionnaire to symptoms of sleep apnea. Among those who were at high risk of sleep apnea 
to the Berlin questionnaire (2 or more categories where the score is positive), the prevalence of 
OSA was 88%.27 A study with all male participants aged ≥40 years showed that CKD was 
associated with OSA (apnea-hypoapnea index [AHI]≥10/hour OR=1.9, 1.1, 4.7; AHI≥30/hour 
OR=2.6, 1.1, 6.2).28 The prevalence of OSA was 67% among non-dialysis stage 3b to 4 CKD 
patients and body adiposity (total and upper) was associated with the presence and severity of 
OSA.29 Alterations in chemoreflex responsiveness, pharyngeal narrowing due to fluid overload, 
and accumulation of uremic toxins might be the mechanisms through which CKD predispose to 
the occurrence of OSA.12 However, most studies were limited to small sample size, a single 
race/ethnicity, and the occurrence of prevalent OSA in which reverse causation may occur 
between CKD and OSA. 
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Our study has several advantages. First, this study has a large sample size of 3.5 million 
veterans and large numbers of persons with incident OSA (n = 417,651) and CKD (100,691 
incident cases and 546,556 baseline prevalent cases). Moreover, since there is no single 
mediation method that can be assured to provide valid and precise results, we used four 
approaches that have different advantages and limitations to provide some confirmation of our 
findings. For example, the 4-way decomposition method provided a comprehensive 
understanding of the mechanistic role of CKD in explaining the total effect of race/ethnicity on 
OSA, while dynamic path mediation analysis enabled us to account for censoring using survival 
analysis with the mediator and confounders treated as time-dependent. Additionally, flexible 
mediation analysis and dynamic path analysis enabled us to deal with the effects of 
race/ethnicity on mediator-outcome confounders in different ways.  
Some limitations of the study should be noted. Misclassification of OSA and CKD may 
occur because of the usage of claims data and limited information on polysomnography to 
define OSA. Moreover, residual confounding may be another problem since we did not have 
information on certain risk factors for CKD or OSA, such as smoking and alcohol consumption. 
Finally, the study population was comprised of mostly Whites Blacks non-Hispanic males; thus, 
generalization to females, other racial/ethnic groups, and non-veterans is limited.  
In conclusion, the study helped us highlight that most of the racial/ethnic disparity in 
OSA incidence was not explained by mediation or interaction with CKD. However, a modest 
percentage of the Black/White disparity was attributable to the combination of CKD and its 3 
main risk factors. Therefore, the results can assist us in underlining the potential mediation of 
CKD and its risk factors in the path between race/ethnicity especially Blacks and OSA. 
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Interventions to decrease CKD and its risk factors occurrence may combat racial disparity in 
OSA. In this way, we gain more insight into possible racial disparities in OSA risk, which might 
lead to medical treatments or other interventions for reducing those disparities, e.g., by 
treating or preventing CKD, possibly focusing on Blacks. Future work could address the role of 
multiple mediators (CKD and other risk factors) in the pathway between race/ethnicity and 
incident OSA. As new and refined methods of mediation analysis are developed to handle the 
many types of data and potential sources of bias encountered in these analyses, they should 
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Tables and figures 
 
Table 4.1: List of ICD-9, ICD-10, and CPT codes used to define obstructive sleep apnea, diabetes, 
hypertension, and CKD 
Type of coding Codes  
ICD-9 for obstructive sleep apnea 327.20, 327.22, 327.29, 327.8 
ICD-10 for obstructive sleep apnea G47.30, G47.33, G47.39, G47.8, G47.9, R06.00, R06.09, 
R06.3, R06.83, R06.89 
CPT for obstructive sleep apnea E0470 and E0601 
ICD-9 for diabetes 250, 35673, 36641, 36201,  36202 
ICD-10 for diabetes E08, E09, E10, E11, E13 
ICD-9 for hypertension 401, 402, 403, 404, 405 
ICD-10 for hypertension I10, I11, I12, I13, I15 
ICD-9 for CKD 016.0; 095.4; 189.0,189.9; 223.0; 236.91; 250.4; 271.4; 
274.1; 283.11; 403; 404; 440.1; 442.1; 477.3; 572.4; 581-
583; 585- 588; 591; 642.1; 646.2; 753.12-753.19; 753.2; 
794.4 
ICD-10 for CKD A18.11, A52.75, B52.0, C64.x, C68.9, D30.0x, D41.0x-
D41.2x, D59.3, E08.2x, E09.2x, E10.2x, E10.65, E11.2x, 
E13.2x, E74.8, I12.xx, I13.0, I13.1x, I13.2, K76.7, M10.3x, 
M32.14, M32.15, N01.x-N08.x, N13.1, N13.1x-N13.39, 
N14.x,N15.0, N15.8, N15.9, N16, N17.x, N18.1-N18.5, 
N18.8, N18.9, N19, N25.xx, N26.1, N26.9, O10.4xx, O12.xx, 






Table 4.2: Summary statistics (mean [SD] or %) of selected measures in the study population of adult 
















Age (mean [SD] 
in years) 
64.0 (15.5) 65.6 (15.3) 58.9 (13.6) 58.6 (17.4) 64.2 (16.4) 
18-44 (%) 10.2 9.1 10.8 20.7 10.6 
45-64 (%) 33.7 28.3 54.8 36.1 34.7 
≥65 (%) 56.1 62.6 34.4 43.2 54.7 
Male (%) 90.8 93.2 85.3 89.9 85.1 
BMIa (mean [SD] 
in years) 
29.0 (5.5) 29.0 (5.5) 29.1 (5.9) 29.1 (5.4) 28.7 (5.5) 
Obesitya,b (%)  37.6 37.4 39.7 38.6 35.1 
Diabetes (%) 25.4 24.9 28.5 29.5 22.1 
Hypertension 
(%)  
52.1 52.5 57.2 46.2 45.1 








68 66 79 81 54 
aMeasured at baseline.  
bDefined as BMI ≥30 kg/m2. 
cBaseline CKD status was based on the presence of at least one of three criteria: having a diagnosis of 
ICD-9 or ICD-10 CKD (see Table 1 for codes); an eGFR <60 ml/min/1.73 m2, using the CKD-EPI formula; 
and the presence of albuminuria (urine albumin-to-creatinine ratio [UACR] ≥30 mg/g). 
dOther NH races included American Indian/Alaska Native (0.81%), Asian (0.86%), Native Hawaiian/Pacific 






Table 4.3: Crude and adjusted hazard ratios (HR; 95% CI) for associations between the covariates of 
interest and OSA incidence rate, by type of model adjustment: Results of Cox regression in the total 
study population (n = 3,529,213)  
Covariate  







Race/Ethnicity    
          White  (ref.)       1 1 1 

















































a Adjusted for race/ethnicity (where needed), age and sex.  
b Adjusted for confounders, including race/ethnicity, age and sex, but not mediators (Fig. 1). The effect 
of diabetes is also adjusted for obesity; the effect of hypertension is also adjusted for obesity and 








Table 4.4: Adjusteda hazard ratios (HR; 95% CI) for the “direct effect,” “indirect effect”, and total effect 
of each race/ethnicity (vs. White non-Hispanic [NH]) on OSA incidence, and the percentage mediated 





HR (95% CI) 
% 
Mediatedf 
Direct effectc Indirect effectd Total effecte 
Model adjusted for age, sex, BMI, diabetes, and hypertension 
Black non-Hispanic 
1.084  




















Model adjusted for age and sex only 
Black non-Hispanic 
1.101  




















a Baseline confounders: age, sex, diabetes status, hypertension status, BMI at baseline.  
b CKD was treated as fixed at baseline.  
cThe direct effect is obtained from the regression coefficient for the race/ethnicity predictor in the Cox 
model with CKD.  
d The HR for the indirect effect is the antilog of the difference between the log HRs for the total effect 
and the direct effect on the log scale.  
e The total effect is obtained from the regression coefficient for the race/ethnicity predictor in the Cox 
model without CKD.  
fPercentage mediated is the difference in log hazard ratios between the models without and with CKD, 
divided by the log hazard ratio from the model without CKD. It is also the log HR for the indirect effect 






Table 4.5: Adjusteda odds ratios (OR; 95% CI) for the 4 component effects of each race/ethnicity (vs. 
White non-Hispanic) on OSA incidence, due to mediation and/or interaction with CKDb: results of the 
4-way decomposition method, using logistic regression 
Component effect 
of race/ethnicity OR (95%CI) Percentage of total effect (95% CI) 
Black Non-Hispanic vs White Non-Hispanic 
Controlled direct 1.098 (1.088, 1.11) 90.4 (89.6, 91.2) 
92.6c 
(91.8, 93.3) 
Reference interaction 1.0024 (1.0021, 1.0027) 2.2 (2.1, 2.3) 
Mediated interaction 1.0007 (1.0006, 1.0008) 0.68 (0.64, 0.71) 
7.4d 
(6.7, 8.2) 
Pure indirect 1.0073 (1.0069, 1.0077) 6.8 (6.0, 7.5) 
Total 1.11 (1.10, 1.11) 100 --- 
Hispanic vs White Non-Hispanic 
Controlled direct 1.12 (1.11, 1.14) 95.3 (95.9, 95.8) 
97.7c 
(97.3, 98.1) 
Reference interaction 1.0030 (1.0027, 1.0035) 2.4 (2.2, 2.5) 
Mediated interaction 1.0003 (1.0003, 1.0004) 0.26 (0.23, 0.30) 
2.3d 
(1.9, 2.7) 
Pure indirect 1.0027 (1.0023, 1.0031) 2.1 (1.7, 2.4) 
Total 1.13 (1.11, 1.15) 100 --- 
Other Non-Hispanic races vs White Non-Hispanic 
Controlled direct 0.907 (0.897, 0.918) 97.1 (96.8, 97.3) 
99.5c 
(99.3, 99.7) 
Reference interaction 0.998 (0.997, 0.998) 2.4 (2.3, 2.6) 
Mediated interaction 1.0001 (1.0000, 1.0001) -0.05 (-0.08, -0.03) 
0.51d 
(0.28, 0.75) 
Pure indirect 0.999 (0.999, 0.999) 0.57 (0.31, 0.83) 
Total 0.904 (0.894, 0.915) 100 --- 
a Baseline confounders: age, sex, diabetes status, hypertension status, BMI.  
b CKD was treated as fixed at baseline. 
cThis % reflects the pure direct effect. 
dThis % reflects the total indirect effect. 
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Table 4.6: Adjusteda odds ratios (OR; 95% CI) for the natural direct effect (NDE), natural indirect effect 
(NIE), and total effect (TE) of race/ethnicity on OSA incidence and percentage of the total, by choice of 




OR (95% CI) 
% 
Mediatedc NDE NIE TEb 




























































aAll the analyses are adjusted for age and sex; and analyses in the top panel (CKD as the only mediator) 
are also adjusted for the 3 CKD risk factors. 
bThe 95% CI for the TE was not computed because it is computationally complex and not needed for 
interpretation of the main findings. Total effect was calculated as the product of NDE and NIE. 
cThe percentage mediated on the risk difference scale is NDE(NIE−1)/(NDE×NIE−1), where NDE and NIE 




Table 4.7: Estimated pure direct effect (PDE), pure indirect effect (PIE), and total effect (TE) of each 
race/ethnicity (vs White non-Hispanic) on OSA incidence, and the percentage mediated by CKD, by 




PDEc PIEd TEe % Mediated 
Black Non-
Hispanic  
-0.0093352 -0.00073 -0.010061 7.2 
Hispanic -0.012495 -0.00031 -0.0128 2.4 
Other non-
Hispanic races 
0.010501 -0.0001 0.010409 -0.9 
 
aCKD (the mediator) and BMI (a confounder) are treated as time-dependent in the analyses; age, sex, 
diabetes, and hypertension are treated as fixed confounders measured at baseline.   
bDay 11 to the end of follow-up  
cPDE is the difference between survival curves S1,0 and S0,0. 
dPIE=TE-PDE. 




Table 4.8: Pros and cons of the 4 mediation methods 
Method Pros Cons 
Difference methoda 
(using an informal ad hoc 
procedure) 
Easy to implement 
No requirement of any 
package or macro  
Assume no interaction between 
race/ethnicity and CKD 
Assume race/ethnicity does not affect 
confounders of CKD-OSA 
Do not deal with data that violate the 
4th assumption 
4-way decompositionb 
(using the SAS procedure) 
Easy to implement with 
current SAS procedure 
Decompose the total effect 
into four parts 
Do not deal with data that violate the 
4th assumption 
Cannot be applied for categorical 
exposure 
  
Flexible mediation analysisc 
(using the medflex R 
package) 
Data with multiple 
mediators 
Weight-based approach and 
imputation-based approach 
to deal with missing 
outcome 
Can obtain standard error 
by bootstrapping or robust 
standard error based on 
sandwich estimator  
Can only estimate indirect effect 
collectively with current version of 
medflex, that is, no path-specific 
indirect effect 
Do not deal with time-to-event 
outcome 
Dynamic path mediation 
analysisd (using a SAS macro) 




Capture the full complexity 
of the mediator 
Takes a lot of time and memory in SAS 
to run 
Confidence intervals can only be 
obtained through bootstrapping which 
takes more than one week to get and is 
not practical 
It is still a novel approach, and should 
be interpreted with caution 
Can only use binary exposure 
Need to group the visits 
Models might not converge if you have 
binary confounders/mediators 
aVanderWeele TJ. Mediation Analysis: A Practitioner’s Guide. Annu Rev Public Health. 2016;37(1):17-32. 
bVanderWeele TJ. A unificaiton of mediation and interaction: a four-way decomposition. Epidemiology. 
2014;25(5):749-761. 
cSteen J, Loeys T, Moerkerke B, Vansteelandt S. Flexible Mediation Analysis with Multiple Mediators. Am 
J Epidemiol. 2017;186(2):184-193. 
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The purpose of this dissertation was to disentangle the complicated relations between 
sleep problems, especially  obstructive sleep disorder (OSA) and chronic kidney disease (CKD). 
In chapter 2, the objectives were to estimate the prevalence and temporal trends of five self-
reported sleep problems and to examine the associations of those sleep problems with CKD 
prevalence and mortality by CKD status, using data from National Health and Nutrition 
Examination Surveys (NHANES). We concluded from the findings that severity of CKD was 
monotonically associated with sleep problems. Excessive sleep and nocturia were strongly and 
consistently associated with all CKD measures, and excessive sleep was most strongly 
associated with all-cause mortality. In chapter 3, we estimated the point and period prevalence 
of OSA among persons with and without CKD, using a method for period prevalence that takes 
into account left censoring of veterans followed back for different durations. We also examined 
the associations between certain covariates and OSA prevalence among non-CKD and CKD 
populations. We found that the population burden of OSA, reflecting both point prevalence at 
the index time and period prevalence in the previous 5 years, was quite high in U.S. veterans, 
especially among men with CKD. Finally, in chapter 4, we evaluated the extent to 
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which the excess incidence of OSA among minority racial/ethnic groups of veterans, 
relative to Whites, could be explained by CKD acting as a mediator of the race/ethnicity effects. 
The results indicate that most of the racial/ethnic disparity in OSA incidence was not explained 
by mediation or interaction with CKD; however, about 30% of the Black/White disparity in OSA 
was attributable to the combination of CKD and its 3 main risk factors—diabetes, hypertension, 
and obesity. 
  The findings of the dissertation highlight the potential clinical importance of addressing 
this topic by both primary care providers as well as by specialists. The high prevalence of OSA 
especially among US male veterans with CKD suggests that extra attention of sleep OSA 
detection and management should be paid to this population. Controlling the potential 
mediation of the occurrence of CKD and its risk factors may combat racial disparity in OSA 
incidence especially for Blacks versus Whites. This could lead to medical treatments or other 
interventions for reducing those disparities, e.g., by treating or preventing CKD risk factors, 
especially in Blacks.   
In chapter 4, we used four types of mediation analysis: the difference method: 4-way 
decomposition, flexible mediation analysis and dynamic path analysis. The latter three methods 
have different statistical advantages and limitations for dealing with our data so they 
complement each other; the first method, which is simpler and has been used informally for 
many years in epidemiology, is used for comparison. The percentages of the total race/ethnicity 
effects mediated by CKD were similar using all 4 mediation methods. Comparing the results 
from different mediation analysis methods could be a good strategy to examine the mediating 
role of variables of interest in future studies. However, there is a need for a general analytic 
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framework of mediation analysis that accommodates all the conditions and constraints we had 
to deal with. As new and refined methods of mediation analysis are developed to handle the 
many types of data and potential sources of bias encountered in these analyses, they should 
prove to be valuable in designing effective interventions for clinical practice.   
To better understand the implications of these results, future studies could address the 
disease burden of CKD and OSA among both US general population and the US veterans. Future 
studies can be done to investigate the clinical outcomes of aggressive treatment of renal 
dysfunction such as examining the estimated effect of the change in glomerular filtration rate 
and OSA occurrence and prognosis. Further, future research is needed to identify other 
potential mediators of reducing the racial disparity of OSA. Potential mediators include risk 
factors of CKD and possibly other risk factors of OSA such as social economic status. 
